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ABSTRACT
The oligonucleotide therapeutics field has seen re-
markable progress over the last few years with the ap-
proval of the first antisense drug and with promising
developments in late stage clinical trials using siRNA
or splice switching oligonucleotides. However, effec-
tive delivery of oligonucleotides to their intracellular
sites of action remains a major issue. This review
will describe the biological basis of oligonucleotide
delivery including the nature of various tissue bar-
riers and the mechanisms of cellular uptake and in-
tracellular trafficking of oligonucleotides. It will then
examine a variety of current approaches for enhanc-
ing the delivery of oligonucleotides. This includes
molecular scale targeted ligand-oligonucleotide con-
jugates, lipid- and polymer-based nanoparticles, an-
tibody conjugates and small molecules that improve
oligonucleotide delivery. The merits and liabilities of
these approaches will be discussed in the context of
the underlying basic biology.
AN OVERVIEW OF OLIGONUCLEOTIDE THERAPEU-
TICS
The initial advent of antisense and siRNA oligonucleotides
sparked high hopes for their eventual use in treatment of
disease. However, these early expectations remained largely
unfulfilled as first generation oligonucleotides failed tomeet
therapeutic end points in a number of clinical trials. After a
period of disappointment, the field of oligonucleotide ther-
apeutics has now been re-invigorated (1). This is due to the
convergence of several developments including improved
chemistries, better understanding of the basic biology of
oligonucleotides, more sophisticated delivery systems and
most importantly, increasing success in the clinic. The 2013
approval of the first major antisense drug, Kynamro R© (2),
an inhibitor of apolipoprotein B expression, was accompa-
nied by promising clinical trials involving siRNA (3) and
splice switching oligonucleotides (SSOs) (4). More recently,
a number of clinical trials utilizing various types of oligonu-
cleotides have reported impressive results. Some examples
might include a use of a receptor-targeted siRNA conju-
gate (5), strong effects on liver diseases using antisense with
novel chemical modifications (6,7), anti-cancer effects with
a miRNA (8) and treatment of a neurodegenerative disease
via intrathecal administration of a SSO (9). More detailed
summaries of selected current clinical studies are provided
in several recent reviews (10–13).
Despite these advances at the clinical level, effective de-
livery of oligonucleotides in vivo remains a major challenge,
especially at extra-hepatic sites (13–15). Various strategies
are being pursued including chemical modification of the
oligonucleotide itself, use of various lipid or polymeric
nanocarriers, linking oligonucleotides to receptor targeting
agents such as carbohydrates, peptides or aptamers, and use
of small molecules to enhance oligonucleotide effectiveness.
The intent of the current article is to provide a broad but an-
alytic review of the oligonucleotide delivery area. The em-
phasis will be on basic biological aspects rather than recent
clinical developments. There are an enormous number of
publications in this area, far too many to be cited in their
entirety. Thus the focus in this review will be on reports
that stand out because of their novelty, or that provide im-
portant mechanistic information, or that display significant
translational potential. This article will also convey the au-
thor’s personal view on the future evolution of the oligonu-
cleotide delivery area.
BASIC INFORMATION UNDERLYING OLIGONU-
CLEOTIDE THERAPEUTICS
The scope of the oligonucleotide therapeutics field has ex-
panded substantially over the last few years as additional
types of nucleic acids are used and as new targets are ad-
dressed. One of the most exciting developments is the real-
ization that thousands of non-codingRNAs play important
roles in cellular function (16) and that these entities can be
readily manipulated using oligonucleotides (17). A contin-
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uing thrust in the field is the pursuit of clinical problems
that are not easily addressed with small molecule drugs.
Thus there has been emphasis on relatively rare disorders
for which no current therapy exists. The various therapeu-
tic approaches currently under investigation involve several
types of nucleic acids with different chemistries and mech-
anisms of action; therefore it seems worthwhile to briefly
review some basic aspects of oligonucleotide biology and
chemistry.
Basic mechanisms of oligonucleotide actions
Classic single stranded antisense oligonucleotides (ASOs)
primarily act in the nucleus by selectively cleaving pre-
mRNAs having complementary sites via an RNase H de-
pendent mechanism (18). Although ASOs can also act by
translation arrest, they are currently primarily used as ‘gap-
mers’, having a central region that supports RNase H activ-
ity flanked by chemically modified ends that increase affin-
ity and reduce susceptibility to nucleases (19). SSOs are a
form ofASO; however they are fullymodified so as to ablate
RNase H activity and allow interaction with nuclear pre-
mRNA during the splicing process. SSOs can be designed
to bind to 5′ or 3′ splice junctions or to exonic splicing en-
hancer or silencer sites. In doing so they canmodify splicing
in various ways such as promoting alternative use of exons,
exon exclusion or exon inclusion (20). SSOs are very flex-
ible tools and are seeing increasing use in therapeutic ap-
proaches (21).
RNA interference (RNAi) is a fundamental endogenous
mechanism for control of gene expression (22). It can in-
volve selective message degradation, translation arrest or
modulation of transcription (23). Both endogenous miR-
NAs and chemically synthesized externally administered
siRNAs utilize Argonaute-containing RISC complexes to
regulate gene expression (24,25). With siRNA, selective
cleavage of mRNA in the cytosol involves Argonaute 2-
containing complexes and requires essentially complete
complementarity between the siRNA ‘guide’ strand and the
target, usually within the coding region of the message. Be-
cause of their selectivity, siRNAs have seen widespread use
in the laboratory and there is great interest in their po-
tential therapeutic applications (26). With miRNA, partial
complementarity, often in 3′-untranslated regions, leads to
translation arrest followed by message degradation; this in-
volves Argonaute proteins and largely takes place in cyto-
plasmic P-bodies. As mentioned above, miRNA can also
regulate transcription within the nucleus by utilizing other
forms of RISC complexes (27). Since miRNA recognition
involves only partial complementarity, a single miRNA can
influence expression of multiple mRNAs. This lack of selec-
tivity can be a problem, but it may also be an advantage in
that it can provide coordinate regulation of an entire set of
genes. ASOs can act as miRNA antagonists (antagomirs)
thus potentially increasing expression of miRNA-regulated
genes.
Observations from the ENCODE project indicate that
non-coding RNAs (ncRNAs) account for up to 75% of the
transcripts from the human genome. There is a bewildering
variety of short and long ncRNAs and understanding of
their biological functions is still at an early stage (28). How-
ever, in many cases non-coding RNAs are involved in nega-
tive regulation of gene expression (17). Thus ASOs comple-
mentary to a ncRNA sequence can act as antagonists and
promote upregulation of expression of genes regulated by
the ncRNA.While attempts to therapeutically exploit ncR-
NAs are just beginning, there is a great deal of interest in
the potential of this approach (29).
Another emerging thrust involves possible therapeutic
use of chemicallymodifiedmRNA. In vitro transcribedmR-
NAs incorporating modified bases can effectively express
proteins in vivo while having reduced effects on the innate
immune system (30). In effect this serves as a transient form
of gene therapy. This technology may be particularly useful
in the context of stem cell therapies (31).
Thus a variety of nucleic acids are now being consid-
ered as potential agents for disease therapy. However, there
are inevitably problems associated with any therapeutic ap-
proach. For antisense and siRNA off-target actions due to
partial complementarity remain a concern, although chem-
ical modifications can be helpful in this regard. Further,
the extent of this type of problem is easily evaluated using
contemporary methods for quantitating mRNA expression
such as ‘gene chips’ or RNA-Seq. A more complex issue in-
volves interaction with the innate immune system (32). Ex-
ogenous nucleic acids can trigger inflammatory responses
via interactions with pattern recognition receptors includ-
ing membrane-bound Toll-like receptors (TLRs) or cytoso-
lic RIG-I family receptors (33). While undesired effects on
innate immunity are a major problem for use of ASOs and
siRNAs in therapeutics, the converse aspect is that oligonu-
cleotides can be used tomodulate the innate immune system
in useful ways by acting as agonists or antagonists of TLRs
or RIG-I (34–37). Other problems for oligonucleotides in-
clude potentially undesirable interactions with blood com-
ponents (38), or with intracellular proteins (39), and rapid
clearance via the kidney (40).
Chemical modifications of oligonucleotides
Recent advances in oligonucleotide therapeutics have heav-
ily depended on progress in themedicinal chemistry of these
molecules. A number of excellent reviews provide a compre-
hensive account of oligonucleotide chemistry (41–43); thus
this section is simply a brief recapitulation designed to set
the stage for discussion of the delivery of the various types
of oligonucleotides.
Phosphorothioates. The phosphorothioate (PS) backbone
modification has been the keystone for contemporary work
on ASOs and SSOs (44). Although it creates a modest re-
duction in binding affinity, in compensation it provides two
important advantages. First, it improves stability to nucle-
ases in the blood and tissues. Second, it promotes protein
binding and thus supports interactions with albumin and
other blood proteins thereby retarding renal clearance. A
disadvantage is that there are significant toxicities associ-
ated with the protein binding capabilities of PS oligonu-
cleotides (44). The PS modification is fully consistent with
RNase H activity.
Neutral backbones. The phosphorodiamidatemorpholino
oligomer (PMO) and peptide nucleic acid (PNA) modifi-
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cations provide neutral backbones and high resistance to
nucleases; however, they do not support RNase H activity.
Thus PMOs, and to a lesser degree PNAs, have primarily
seen use as SSOs (45).
2′ modifications. Themost widely used alterations at the 2′
sugar position are the 2′-O-Me and 2′-O-(2-methoxyethyl)
(MOE) modifications. Both promote an A-form or RNA-
like conformation and considerably increase binding affin-
ity to RNA, as well as providing enhanced nuclease re-
sistance. Oligonucleotides fully modified at the 2′ position
do not support RNase H activity and thus can be used as
SSOs. However, RNase H dependent antisense effects can
be achieved by use of ‘gapmers’ that contain a central un-
modified section of about seven residues flanked by 2′ mod-
ified regions. Kynamro R©, the first FDA approved ASO, is a
MOE gapmer with a PS backbone. Modification of the 2′
position is also widely used in siRNAwith 2′-O-Me and 2′–
F being the most common. An important aspect for siRNA
is that 2′ modifications can reduce both immunostimulatory
effects (33) and off target effects (26).
Bridged rings. The locked nucleic acid (LNA) (46) chem-
istry as well as constrained ethyl (cEt) and tricyclo-DNA
(tc-DNA) modifications involve bridging of the sugar ring.
They each promote anRNA-like structure, display nuclease
resistance andmost importantly, provide dramatic increases
in binding affinity. They do not support RNase H activity,
but can be used effectively in antisense gapmers or as SSOs.
Novel approaches. Recently several highly novel ap-
proaches to oligonucleotide chemistry have been developed.
A strategy pursued by Dowdy et al. entailed a complete re-
design of the synthesis of siRNA so as to reversibly mask
the negative charges of the phosphate backbone thus creat-
ing neutral siRNAs (47). Although this did not in itself al-
low increased delivery to cells, it enhanced binding to serum
protein thus reducing renal clearance. Further, the neutral
siRNAs could be effectively delivered to tissues by conjuga-
tion with a targeting ligand. A development of far reaching
significance is the advent of XNAs, polymers formed from
building blocks not found in nature that mimic many of the
properties of RNA and DNA (48). Although this technol-
ogy has yet to find therapeutic application, it clearly opens
up many exciting possibilities.
CHALLENGES FOR NUCLEIC ACID DELIVERY
The key problem for oligonucleotide-based therapeutics is
to deliver the active oligonucleotide to its site of action in
the cytosol or nucleus of cells within tissues. There are really
two parts to this problem. The first is to convey the oligonu-
cleotide to the tissue of therapeutic interest while minimiz-
ing exposure of other tissues. The second is to convey the
oligonucleotide to the right intracellular compartment. The
delivery problem can be usefully considered in terms of bar-
riers to movement of oligonucleotides within the body. The
relative importance of the various barriers will depend on
the chemical and physical properties of the oligonucleotide
therapeutic being employed. For example, the biodistribu-
tion of antisense or siRNA oligonucleotides when used as
individual molecules will obviously be quite different from
that attainedwhen some type of nanoparticle carrier is used.
Tissue barriers to delivery
The first challenge concerns getting the oligonucleotide to
the tissue of therapeutic interest. In this section we will con-
sider several barriers that influence oligonucleotide access
to tissue sites, as schematically illustrated in Figure 1.
The vascular endothelial barrier. In most tissues the cap-
illary lumen is surrounded by a layer of endothelial cells
that tightly abut upon each other and are joined together
by VE-cadherin containing adherence junctions and by oc-
cludin and claudin-containg tight junctions, thus forming a
barrier between blood and the parenchymal space (49,50).
Molecules in the blood can be transported across the en-
dothelial barrier by two routes. The first is paracellular
transport that occurs through the junctions between cells
and is limited to molecules of ∼6 nm diameter or less.
The second is caveolar-mediated transcytosis that carries
albumin and other large proteins across the endothelium
within vesicles of about 70 nm. Both forms of transport are
tightly regulated by various signaling systems. In most tis-
sues neither transport system is capable of efficiently con-
veying typical ∼100 nm nanoparticles. However, in some
tissues, such as liver and spleen, there are gaps or fenes-
trations between the endothelial cells, thus allowing egress
of larger macromolecules and particles. Endothelial per-
meability is also increased in sites of inflammation and in
some tumors. This last is a basis of the ‘Enhanced Perme-
ation Retention’ (EPR) effect that has evoked much inter-
est among proponents of nanoparticle-based drug delivery
for cancer therapy. The concept is that the increased leak-
iness of tumor vasculature will allow nanoparticles to se-
lectively accumulate at these sites (51). While this is clearly
true for a number of rapidly growing xenograft tumors, not
all xenografts display a strong EPR effect, and the extent of
the effect in human tumors is rather unclear (52,53). Thus
there are concerns regarding reliance on the EPR effect as
a delivery strategy. In summary, the vascular endothelium
allows ready passage of molecules the size of individual
oligonucleotides into many tissues, but limits the passage
of nanoparticles, except in certain sites such as the liver.
The reticuloendothelial system (RES). The mononuclear
phagocytes of the reticuloendothelial system (RES) pro-
vide a key aspect of host defense through their ability to
engulf and inactivate pathogens (54). Their highly devel-
oped phagocytic capacity also allows them to internalize
a wide variety of particulate materials including denatured
proteins, apoptotic cell fragments and man-made nanopar-
ticles. The kupffer cells of the liver sinusoids, as well as
splenic macrophages, play an especially prominent role in
the clearance of nanoparticles from the blood and much ef-
fort has been devoted to finding ways to evade uptake by
these cells. However, this has been only partially successful
despitemany attempts tomodify nanoparticle surfaces with
polyethylene glycol (PEG) or other inert polymers (55,56).
Thus the administration of oligonucleotides incorporated
into liposomes or other nanoparticles will usually result in







Figure 1. Tissue barriers to oligonucleotide delivery. Barriers for blood to parenchyma transfer are depicted. The star-shaped forms represent ‘free’ oligonu-
cleotides or molecular scale oligonucleotide conjugates. The blue circles represent oligonucleotides incorporated in nanoparticles. Tissue parenchyma is
represented as pink or tan (brain) coloration. (A) Blood brain barrier. The tightly apposed endothelial cells as well as pericytes and astrocyte processes
present an essentially impenetrable barrier for both free oligonucleotides and oligonucleotides in nanoparticles. (B) Blood tissue barrier. In many tissues
oligonucleotides can readily cross the endothelium by diffusion through paracellular routes. Permeation of nanoparticles is much more limited and may
take place via transcytosis. (C) Blood liver barrier. The fenestrated endothelium in liver and spleen is easily permeated by both free oligonucleotides and
nanoparticles. However, the liver kupffer cells avidly take up nanoparticles.
a large fraction of the material being taken up by the cells
of the RES, particularly the kupffer cells (57). Additionally,
the RES also plays an important role in uptake and clear-
ance of individual ‘free’ oligonucleotides. Thus mononu-
clear phagocytes express a number of cell surface receptors,
including integrins and scavenger receptors, which can po-
tentially be involved in uptake (19,58,59). The role of scav-
enger receptors in uptake of free PS oligonucleotides in vivo
is somewhat controversial (60). Nonetheless, such receptors
have clearly been implicated in the uptake of morpholino
oligonucleotides conjugated with cell penetrating peptides
(CPPs) (61). In summary, the phagocytic cells of the RES
are important modulators of the biodistribution of both
‘free’ and nanoparticulate oligonucleotides (62).
Renal excretion and effects on pharmacokinetics and biodis-
tribution. The kidney plays an important role in the phar-
macokinetics and biodistribution of oligonucleotides. Typ-
ically molecules with sizes of 3–6 nm or less can be ultra-
filtered by the kidney (63); many types of oligonucleotide
fall in this range and thus can be rapidly excreted by the re-
nal route. PS ASOs bind to plasma proteins thus slowing
their renal clearance and permitting broad distribution to
tissues, with accumulation to the highest levels in liver and
kidney (64). However, the kidney is also the primary route
of excretion of phosphorothioates although this is a rela-
tively slow process and mainly involves nuclease degrada-
tion products. In contrast, siRNA and uncharged oligonu-
cleotides do not bind extensively to plasma proteins (40,65).
Thus they are cleared by the kidneymuchmore readily than
phosphorothioates and tend to accumulate at lower levels
in tissues. For siRNAs, the liver and kidney are the major
sites of accumulation (66). Unchargedmorpholino oligonu-
cleotides are rapidly cleared by the kidney largely as intact
molecules and display lower levels of tissue accumulation
than phosphorothioates (65); the kidney and the liver are
the primary tissues of distribution for these molecules. Thus
renal clearance plays an important role in the pharmacoki-
netics and biodistribution of essentially all types of ‘free’
oligonucleotides.
The blood brain barrier and therapy of CNS diseases. An
exciting and somewhat surprising recent development is the
effective use of oligonucleotides for therapy of diseases of
the central nervous system (CNS), despite the difficulties in
accessing this compartment (67,68). The blood brain bar-
rier (BBB) is comprised of tightly linked endothelial cells
supported by a network of pericytes and astrocyte processes
and is impervious to molecules as small as sucrose (67).
The BBB is also largely impervious to oligonucleotides; as
discussed below, there have been many attempts to deliver
oligonucleotides across this barrier, but these have met with
only modest success. Consequently, the most promising re-
sults in addressing CNS diseases have come through direct
administration of oligonucleotides, usually by intrathecal
injection.When administered by this route oligonucleotides
distribute broadly in the CNS and are taken up by both neu-
rons and glial cells (68). A variety of intractable diseases
have been approached in thismanner at both the pre-clinical
and clinical trial levels. For example, chemically modified
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ASOs have been used to treat models of Huntington’s dis-
ease (69) as well as familial forms of Alzheimers and ALS
(70). Correction of the defect in spinal muscular atrophy in-
volves the use of SSOs (71) and has progressed from animal
experiments to phase II clinical trials (72). A particularly
impressive recent study in amouse model of Angelman syn-
drome used ASOs to reduce levels of a lncRNA resulting in
‘un-silencing’ of the key gene in this disease (73).
Obviously systemic administration is preferable to di-
rect CNS administration and thus there have been many
attempts to convey oligonucleotides across the BBB. Per-
haps the most promising involve conjugates of PMOs with
CPPs (74). There have been several reports of CPP-PMO
conjugates reaching the brain (67,75). However, there re-
main concerns about the possible systemic and CNS toxici-
ties of the polycationic CPPs. Another interesting develop-
ment is a recent report that systemically administered tri-
cyclic SSOs had an effect in the brain (76). Although the
tricyclic modification provides increased affinity it is un-
clear why these molecules should cross the BBB while other
oligonucleotides with similar backbones do not. It has been
suggested that the tricyclos aggregate to form nanopar-
ticles, however there are also problems with nanoparticle
delivery to the brain. Thus there have been many studies
using various nanoparticles seeking to deliver drugs, pep-
tides or oligonucleotides across the BBB (77), but usually
with limited success. One potentially interesting approach
is to link nanoparticles to transferrin receptor ligands or
to anti-receptor antibodies, thus making use of a transfer-
rin receptor-mediated transcytotic route across the vascu-
lar endothelium (78–80). However, as yet there are no re-
ports of functional in vivo delivery of oligonucleotides by
this approach. Another interesting strategy involves use of
a rabies virus peptide to target siRNA nanoparticles to
neurons (81,82). However, since the receptors for this pep-
tide are on neurons rather than brain capillary endothe-
lium it is unclear how this would help to traverse the BBB.
A further consideration is that even if nanoparticles cross
the brain endothelium their relatively large size will re-
strict their diffusion through the extracellular matrix of
brain parenchyma (83) whereas ‘free’ oligonucleotides read-
ily spread throughout the brain. Thuswhile there are a num-
ber of reports in the literature purporting to achieve deliv-
ery across the BBBwith nanoparticles, it is important to ask
whether the BBB was intact in these studies or was it com-
prised by infection, cancer, inflammation or the toxic prop-
erties of the delivery vehicle itself. In summary, systemic de-
livery of oligonucleotides to the CNS remains a challenge
that is largely unresolved.
Receptors and cell-selective targeting
There is increasing interest in ‘targeting’ oligonucleotides to
specific cell types within the body. Perhaps the best way to
do this is to conjugate the oligonucleotide (or its nanocar-
rier) to a ligand that interacts selectively with a cell sur-
face receptor. Ideally, one would like to utilize a recep-
tor that is expressed only in a single tissue, that is abun-
dant, that rapidly and extensively internalizes, and forwhich
high affinity ligands are readily available. Obviously, no re-
ceptor fully meets this ideal. However, there are many in-
stances where receptor mediated targeting can greatly assist
oligonucleotide delivery. Experience with targeting of anti-
bodies and nanoparticles suggests that the key beneficial ef-
fect of targeting relates primarily to increased uptake at the
cellular level rather than to overall changes in biodistribu-
tion (84,85). The paragraphs below briefly describe some of
the basic characteristics of several important receptor fam-
ilies, emphasizing the aspects that are relevant to targeted
delivery. A later section of the review will discuss studies
that use these receptors to target oligonucleotides to specific
cells.
Integrins. The integrins comprise a family of het-
erodimeric cell surface receptors that are differentially
expressed on a variety of cell types. The 18  and 8  chains
give rise to 24 distinct integrins in mammals. Integrins
serve both as structural proteins and as components of the
signal transduction machinery (86,87). Thus integrins link
the cytoskeleton to large extracellular matrix proteins such
as fibronectin and laminin. They also directly generate
intracellular signals themselves, primarily through focal
adhesion kinase (88). As well they can modulate other sig-
naling processes, including the MAP Kinase pathway (89).
Integrins are expressed at relatively high levels, typically in
the range of hundreds of thousand of copies per cell (90).
Integrins are actively internalized by clathrin-dependent
and independent endocytotic mechanisms and usually
recycle to the cell surface via Rab4- or Rab-11 medi-
ated trafficking pathways (91). While many integrins are
rather ubiquitously expressed, there are several examples
of tissue or disease state selective expression including
alphaIIbbeta3 on platelets, beta2 integrins in leukocytes
and alphavbeta3 expression in angiogenic endothelia and
in certain tumors (92,93). This last has engendered a great
deal of interest in using alphavbeta3 selective ligands for
tumor targeting (94). In summary, integrins offer many
potential advantages for targeting including relatively high
expression levels, rapid recycling and the availability of
well-defined peptide and small molecule ligands.
GPCRs. The∼800G protein-coupled receptors (GPCRs)
comprise the largest receptor family in the human genome
(95). The signaling activity of GPCRs is tightly linked with
their endocytosis and intracellular trafficking (96). Inter-
nalization via clathrin coated pits desensitizes the receptor
and reduces signaling via ‘classical’ secondmessengers such
as cyclic adenosine monophosphate (AMP), while activat-
ing new signaling pathways involving -arrestin and c-Src
(97). GPCRs often have distinct distributions in tissues or
in disease states. For example, overexpression of the gas-
trin releasing peptide receptor has been observed in a num-
ber of cancers and this has been exploited therapeutically
(98). There is a huge stockpile of highly selective GPCR lig-
ands since such agents account for about 40% of all clin-
ically utilized drugs (http://www.iuphar-db.org/index.jsp).
Thus GPCRs offer some advantages for targeting, partic-
ularly in terms of differential tissue expression and ligand
availability. However, there are also disadvantages. One is
that these receptors are often expressed at relatively low lev-
els compared to other receptor families, typically between
103 and 104 copies per cell (99). Another is that, in most
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cases, efficient internalization takes place only when the re-
ceptor is presented with an agonist ligand but not an antag-
onist.
RTKs. The human receptor tyrosine kinase (RTK) fam-
ily is comprised of 58 members grouped into multiple sub-
families. The basic mechanism of activation of RTKs in-
volves binding of the specific growth factor causing recep-
tor oligomerization thus activating the tyrosine kinase and
triggering cell signaling (100). The intracellular trafficking
of RTKs is a key aspect of their function (101); the EGFR
is well studied in this regard and can serve as an example
for other receptors. After ligand binding, the EGFR enters
early endosomes and is subsequently trafficked to late endo-
somes (LEs) and then to lysosomes, where both ligand and
receptor are degraded thus terminating signaling (100). Dif-
ferential expression of certain RTKs is observed in various
tissues or disease states including over-expression of HER2
in some forms of breast cancer (102), overexpression of Trk
family members in neuronal tissues (103), and enhanced
expression of VEGFR2 in vascular endothelial cells (104).
The expression of RTKs can vary widely, ranging from 103
to 106 copies per cell (105,106). The endogenous ligands for
RTKs are all relatively large polypeptides and thus are not
ideally suited for delivery approaches. However, there are
many high affinitymonoclonal antibodies for RTK external
domains (107) that can be used as targeting reagents, con-
verted to Fab fragments, or reconfigured as scFv reagents
(108). In summary, the RTKs offer a mixed picture for tar-
geting purposes. An advantage is that they are often highly
expressed. However, this is offset by the fact that, upon in-
ternalization, the receptor is largely degraded rather than
recycling to the cell surface. Another disadvantage is the
lack of relatively small ligands that can be readily coupled
to oligonucleotides or nanocarriers.
TLRs. The 10 members of the TLR family in humans pri-
marily respond to ligands that contain pathogen associated
molecular patterns derived frombacterial cell walls ormem-
branes and from bacterial or viral nucleic acids (109,110).
The TLRs are comprised of an external ligand binding
domain, a single transmembrane segment and a cytosolic
TIR (Toll/IL-1R) domain. There are two groups of TLRs;
members of the first group reside at the plasma membrane
as monomers and respond to lipid and protein ligands by
dimerization to initiate signaling. Members of the second
group are found as dimers within the endoplasmic retic-
ulum and endosomes and are activated by exogenous nu-
cleic acids in a process that involves conformational alter-
ation of the receptor. Thus TLR 9 is activated by DNA
with unmethylated CpGs, TLR 7, 8 are activated by sin-
gle stranded RNAs, while TLR3 is activated by ds-RNA.
The issue of howTLRs discriminate exogenous and endoge-
nous RNA is an area of active investigation. Signal trans-
duction by TLRs involves interaction with cytosolic pro-
teins such as Myd88 and TRIF that also contain TIR do-
mains. Downstream responses include induction of genes
for inflammatory cytokines as well induction of interferons.
TLRs are most highly expressed in macrophages and den-
dritic cells but many cell types express at least one member
of this receptor family (111). However, there seems to be lit-
tle quantitative information in the literature regarding TLR
expression at the protein level. The plasmamembraneTLRs
are internalized by clathrin mediated endocytosis; this both
downregulates receptor availability and is important to as-
pects of the signaling process (112). There is little informa-
tion on the trafficking of the endosomal TLRs subsequent
to the ligand binding event. In terms of targeted delivery
of oligonucleotides, TLRs offer one important advantage,
their ability to bind nucleic acids. Thus the investigator can
synthesize ‘chimeric’ oligonucleotides that contain an active
segment such as an siRNA and a delivery segment such as
a CpG motif.
Scavenger receptors. This cohort of transmembrane re-
ceptors constitutes a functional family rather than one de-
marcated by common sequence or structure (59,113). Their
role is to remove modified or damaged endogenous macro-
molecules or cells and to clear the body of foreign macro-
molecules or particles. The various scavenger receptors tend
to bind a wide variety of ligands with extensive overlap
of binding between different receptors. However, a com-
monality is the tendency to bind polyanions, probably via
patches of cationic residues on the receptor external do-
main. The scavenger receptors have been grouped into eight
sub-families (A-I) of which the class A (SCARA) subfam-
ily is most widely studied. Despite having very short cy-
toplasmic domains several scavenger receptors are known
to participate in signal transduction processes, probably
via formation of complexes with other cell surface recep-
tors. Scavenger receptors efficiently internalize via endocy-
tosis or phagocytosis thus conveying their ligands into en-
domembrane compartments. It is difficult to use these re-
ceptors for targeting purposes because of their widespread
expression and diverse and overlapping ligand binding abili-
ties.However, whether intended or not, it seems increasingly
likely that scavenger receptors play a substantial role in the
cellular uptake of both ‘free’ oligonucleotides and nanocar-
riers (62).
The asialoglycoprotein receptor (ASGR). This receptor
is a C-type lectin that is predominantly displayed on the
plasma membranes of hepatocytes (114). Its physiological
role is to clear de-sialyated glycoproteins from blood but
it also is almost ideal for targeted delivery of materials to
the liver. The asialoglycoprotein receptor (ASGR) is ex-
pressed at extremely high density (about 5 × 105 copies per
hepatocyte) and is rapidly internalized and recycled with a
turnover time of about 20 min. The preferred ligand for the
ASGR is a triantennary sugar terminating in galactose or
N-acetyl galactosamine. Upon ligand binding, the ASGR is
accumulated in coated pits where it rapidly internalizes and
is then trafficked to early/sorting endosomes. The low pH
endomembrane environment causes ligand-receptor disso-
ciation allowing the ASGR to rapidly return to the plasma
membrane while the ligand is trafficked to lysosomes. Thus,
the ASGR has many desirable aspects for targeted deliv-
ery of oligonucleotides including cell-type selectivity, high
expression levels, rapid internalization and recycling, and
the existence of well-characterized small ligands. Interest-
ingly, despite being the focus of many liver-directed deliv-
ery strategies, there has been little consideration of the po-
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tential role of the ASGR in signaling. However, it has now
become clear that the ASGR is a signaling receptor and in-
deed is crucially involved in platelet homeostasis through a
JAK-STAT signaling pathway that regulates thrombopoi-
etin production (115).
In addition to the receptors mentioned above there are
obviously many other receptor families that might be used
for oligonucleotide targeting. Interleukin and interferon re-
ceptors, Wnt-family receptors, Transforming growth factor
(TGF)-/activin receptors, the immunoglobulin family re-
ceptors found in lymphoid cells, and the numerous recep-
tors involved in neuronal cell recognition all come to mind
as possibilities. As well, the folate/folate receptor system
has been widely used to target ovarian cancer cells (116).
Each of these receptors must be considered in terms of tis-
sue selectivity, expression levels, rate of internalization and
recycling, and availability of ligands. The properties of sev-
eral receptor families relevant to oligonucleotide delivery
are summarized in Table 1.
Unintended consequences of targeting. While targeted de-
livery of oligonucleotides, drugs and imaging agents has
been the focus of thousands of publications over the last
couple of decades, there has been a surprising lack of em-
phasis on one of the basic consequences of the targeting
process. A ligand that provides effective delivery by virtue
of its high affinity binding to a specific receptor will also
serve as an agonist or antagonist of that receptor. In doing
so it will strongly affect the downstream signal transduction
cascade. Thus the net effect will combine both the sequence
specific actions of the oligonucleotide and the signaling ef-
fects of the targeting agent. It is possible that this may be of
modest importance in short term laboratory experiments,
but if ligand-conjugated oligonucleotides (or nanoparticles)
are to be used for therapy of human disease, the conse-
quences of chronic modulation of key signaling processes
must be considered. While the need to be concerned about
signaling when dealing with GPCRs or RTKs is rather ob-
vious, recent studies reveal that receptors not usually as-
sociated with signaling, including SCARAs and ASGR,
can nonetheless participate in important signal transduc-
tion cascades.
Cellular uptake, intracellular trafficking and endosomal bar-
riers
Upon reaching the cell surface, ‘free’ oligonucleotides,
oligonucleotide conjugates or nanocarriers bearing
oligonucleotides all share essentially the same fate; they are
internalized by endocytosis and then traffic through mul-
tiple membrane-bound intracellular compartments. Thus
most of the oligonucleotide accumulated by cells remains
separated from the cytosol and nucleus by membrane
barriers. The concept of an endosome escape barrier has
become prominent in the literature over the last few years
and is now generally regarded as perhaps the most im-
portant impediment to effective use of oligonucleotides in
therapeutics. Several recent reviews have dealt in detail the
mechanisms of endocytosis and trafficking and how these
impact oligonucleotide pharmacology (117–119). Thus
here we will briefly outline some of the basic aspects most
relevant to oligonucleotide delivery. Figure 2 schematically
depicts some of the processes described below.
Basic aspects of endocytosis. The simple term endocyto-
sis encompasses a variety of complex events whereby cells
take up materials from their surroundings (120). The best-
known internalization mechanism is the coated pit path-
way that utilizes adaptor proteins, a clathrin network, and
the GTPase dynamin to concentrate ligand-bound recep-
tors at the cell surface and then convey them into cells.
Several important physiological processes utilize clathrin-
mediated endocytosis including uptake of transferrin and
low-density lipoproteins, as well as internalization of ago-
nist activated GPCRs (121). Caveolae originate from mem-
brane structures enriched in cholesterol, sphingolipids and
the transmembrane protein caveolin (122). While the role of
caveolae in endocytosis has been questioned at times, it now
seems clear that these compact structures (100 nm) do play
a role in the internalization of certain receptors and their
ligands. For example, some members of the integrin family
as well as certain sodium channels are internalized via the
caveolar pathway (123,124). Multiple additional endocy-
totic pathways occur in cells including ones that do not rely
on clathrin, caveolin or dynamin (125). An important exam-
ple is the CLIC/GEEC pathway that results in the forma-
tion of tubular endosomes that make a large contribution
to fluid phase endocytosis. Another high volume pathway
is macropinocytosis whereby the cells use an actinomyosin-
driven process to pinch off and engulf large amounts of ex-
tracellular fluid. All of these processes have been implicated
to varying degrees in the initial uptake of oligonucleotides.
Increasing evidence indicates that the initial route of endo-
cytosis can be an important determinant of oligonucleotide
pharmacology and that there are both productive and non-
productive paths of cellular uptake (126,127).
Basic aspects of intracellular trafficking. After initial in-
ternalization by endocytosis, oligonucleotides, like all inter-
nalized materials, must traffic through a complex network
of endomembrane compartments each with distinct charac-
teristics and functions. Major membrane-bound compart-
ments include early and recycling endosomes, LEs/multi-
vesicular bodies (LEs/MVBs), lysosomes, the Golgi appa-
ratus and the endoplasmic reticulum. Irrespective of the
original pathway of endocytosis, most substances entering
the cell are initially delivered to early endosomes. Subse-
quently there are two basic fates for materials that reach
the early endosome; they can be shunted to lysosomes for
degradation, or they can be recycled to the plasma mem-
brane and cell exterior (128).
Immediately after internalization, the initial endosomal
vesicle fuses with early/recycling endosomes (EEs) (129).
These are relatively large, tubulated structures usually lo-
cated near the cell periphery and having a pH of about 6.0–
6.5. For many ligand-receptor complexes, the early endo-
some is the site where the receptor and its ‘cargo’ are dissoci-
ated. The free receptor migrates to the tubular region and is
eventually returned to the plasmamembrane via small shut-
tle vesicles, while the cargo remains in the central lumen and
will eventually be delivered to lysosomes for degradation.
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Table 1. Receptor properties relevant to oligonucleotide targeting
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Some receptor characteristics important for oligonucleotide delivery are listed in the table.
The next stage of the trafficking process involves
LEs/MVBs that are the primary stepping-stone on the road
to lysosomes (130). These structures are morphologically
and biochemically distinct from early endosomes, having a
non-tubulated appearance, a perinuclear location and a lu-
men filed with small intraluminal vesicles (ILVs) that have
pinched off from the boundary membrane of this organelle.
Although the major task for LEs is to convey internalized
material to lysosomes, an interesting detour involves the ex-
ternalization of the ILVs as exosomes that can convey ma-
terials to other cells (131).
Ultimately most material internalized by endocytosis is
delivered to lysosomes. These dense organelles are rich in
hydrolases that function in the low pH environment (pH
4.5–5.5) that is maintained by an active V-ATPase proton
pump, thus allowing the hydrolases to degrade proteins,
lipids, carbohydrates and nucleic acids to their constituent
building blocks (132). Besides degrading internalized ma-
terials, lysosomes are also a key part of the machinery for
autophagy whereby cells degrade damaged proteins and or-
ganelles and recycle the constituents (133).
It is important to note that the early endosome to lyso-
some pathway is not linear and that there are several
branches and loops. An important one is the retrograde
trafficking pathway that links endosomes to the trans-
Golgi. A classic example of retrograde transfer is the recap-
ture of mannose-6 phosphate receptors from endosomes to
theGolgi, while their hydrolase ligands are delivered to lyso-
somes (134). Interestingly, several pathogens have ‘hijacked’
this pathway; for example, certain bacterial toxins reach the
cytosol by following the retrograde pathway to the trans-
Golgi and thence to the endoplasmic reticulum (135).
In summary, the pathways of endocytosis and intracel-
lular trafficking are complex and dynamic. Contemporary
imaging technologies (136) are starting to provide detailed
insights into these pathways that will be very helpful in un-
derstanding the fundamental basis of oligonucleotide phar-
macology. However, it remains a challenging problem to
link microscopic observations on the intracellular traffick-
ing of a fluorescent oligonucleotide to the pharmacological
effects of that molecule. Visualization of the bulk distribu-
tion may not reveal minor compartments that are key to
biological activity.
The machinery of intracellular trafficking. There are two
basic ways by which materials can move through the intra-
cellular trafficking network (128,136,137). One involves rel-
atively small shuttle vesicles that convey both luminal and
membrane material between larger endomembrane com-
partments. The other is endosome maturation whereby one
compartment gradually assumes the characteristics of a sec-
ond compartment.
Although differing in detail, all transfer of material via
shuttle vesicles involves several basic steps (138–140). First,
coat proteins help to pinch off small vesicles from the donor
compartment. Second, the shuttle vesicle moves toward the
recipient compartment using actin or tubulin cytoskeletal
machinery. Third, a recognition event occurs between the
shuttle vesicle and the recipient. Fourth, the shuttle vesi-
cle fuses with the recipient compartment and delivers its
contents to the recipient membrane and lumen. This dy-
namic process is very precisely regulated by a plethora of
proteins and multi-protein complexes. Some key examples
include the Rab family of small GTPases, SNARE com-
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Figure 2. Cellular uptake and intracellular trafficking of oligonucleotides. Oligonucleotides enter cells via several endocytotic pathways that vary in
terms of their dependence on clathrin, caveolin or dynamin. These pathways all initially lead to the early/re-cycling endosome compartment; nonethe-
less molecules entering via different pathways can traffic to different downstream destinations. Most internalized oligonucleotide accumulates in late
endosomes/multivesicular bodies (MVBs) and in lysosomes; however, some trafficking to other membrane bound compartments does occur. Oligonu-
cleotides within endomembrane compartments are pharmacologically inert, but a very small portion of internalized oligonucleotide can spontaneously
escape to the cytosol and nucleus. Intracellular trafficking is highly regulated by a large number of proteins and protein complexes. Thus the Rab family
of GTPases regulates many aspects of trafficking and individual members serve as markers for distinct endomembrane compartments. The formation of
MVBs is regulated by the multi-protein ESCRT complex that has recently been demonstrated to play a key role in the effectiveness of oligonucleotides.
This complex also plays a role in exosome formation. The retromer complex may deliver oligonucleotides to the trans-Golgi instead of to lysosomes.
plexes, tethering complexes, the ESCRT complex and the
Retromer complex. These various proteins/protein com-
plexes play important functional roles, but they also serve
as easily recognizable markers for specific endomembrane
compartments.
Members of the numerous (>60) Rab GTPase protein
family serve as molecular switches that regulate many as-
pects of trafficking including vesicle uncoating, movement
along cytoskeletal tracks and the ultimatemembrane fusion
events involving tethers and SNARES (137,141). Rab pro-
teins also serve as excellentmarkers of individualmembrane
compartments and trafficking pathways. For example, Rab5
is a marker for early endosomes while Rab7 identifies LEs.
The shuttle vesicle trafficking process involves coat pro-
teins that assist in the initial formation of the vesicle
(140,142). The generation of clathrin-coated vesicles at the
plasma membrane is a good example, but other types of
coats exist including the COPI proteins involved in Golgi to
ER transport and theCOPII proteins involved in the reverse
process. Disjunction of the clathrin-coated vesicle from the
donor membrane is accomplished by the dynamin GTPase,
but other pinching off mechanisms exist for other types of
vesicles.
Tethering proteins impart selectivity to trafficking by pro-
moting preferential interactions between the vesicle and
the recipient compartment. The coiled-coil tethers and the
multi-subunit tethers comprise the two broad classes of
tethering proteins (143,144). By associating with both Rab
proteins and SNARES, tethers are thought to physically
link the twomembranes destined for fusion. However, some
tethers clearly have multiple functions including possibly
‘proof-reading’ SNARE complexes to assure fusion of the
correct partners.
The final transfer of both themembrane and luminal con-
tents of the shuttle vesicle to the recipient compartment oc-
curs via a fusion process mediated by SNAREs (soluble N-
methylmaleimide sensitive factor attachment protein recep-
tors)(145,146). Vesicle SNARES (v-SNARES) interact with
SNARES on the target membrane (t-SNARES) forming
a four-helix bundle. This undergoes a dramatic conforma-
tional change, inducing fusion of the apposed lipid bilayer
membranes. Only cognate pairs of v- and t-SNARES will
sustain fusion, indicating considerable specificity of the pro-
cess. Re-segregation of the v-SNARES and t-SNARES is
mediated by the ATP-dependent NSF/SNAP protein com-
plex.
Nucleic Acids Research, 2016, Vol. 44, No. 14 6527
An important detour on the pathway between endosomes
and lysosomes is retrograde trafficking between early en-
dosomes and the trans-Golgi (134,135,147). This process
is driven by the retromer that includes a trimeric complex
(Vps26–Vps35–Vps29) that binds to the cytoplasmic tails
of potential cargo proteins. It also includes SNX proteins
that have PX domains that recognize membrane phospho-
inositides and BAR domains that can affect membrane cur-
vature. This results in the tubulation of the EE membrane
and eventual formation of shuttle vesicles that traffic to the
trans-Golgi.
In addition to the shuttle vesicle mechanism, intracellu-
lar trafficking also utilizes processes involving maturation
of one major endomembrane compartment into another
(128,148). Perhaps the best example is the conversion of
EEs to LEs. The Rab5 GTPase plays a key role in the iden-
tity and function of early endosomes (137,149). The ac-
tivating proteins Rabex-5 and Rabaptin-5 stimulate Rab5
on the cytosolic surface of the EE resulting in the recruit-
ment of Rab5 effectors including the tethering factor EEA1
and the PI 3-OH kinase Vps34. Initially this process is self-
sustaining allowing the EE to interact with other EEs and
to recycle receptors and othermembrane constituents to the
cell surface. Eventually other proteins are recruited to the
EE that drive displacement of Rab5 and association with
Rab7. Two sets of effectors, the SAND-1/Mon complex and
theHOPS complex, seem towork in tandem in the EE toLE
maturation (128). In parallel to the Rab5 to Rab7 conver-
sion, the endosome loses ability to interact with EE partners
and instead acquires the ability to associate with LE part-
ners. One of the key aspects of the EE to LE maturation is
the formation of ILVs (150). This process helps to concen-
trate selected proteins and lipids in the LE lumen directing
them to lysosomal degradation. The fivemulti-protein com-
plexes of the ESCRT (endosomal sorting complex required
for transport) machinery, ESCRTs 0–III and Vps4–Vta1,
recognize ubiquitinated membrane proteins and drive them
into invaginations that ultimately form ILVs within the lu-
men of the LE/MVB (151).
How is all this trafficking complexity linked to oligonu-
cleotide delivery? As an example, in an extremely impor-
tant recent investigation of basic aspects of oligonucleotide
trafficking, Wagenaar et al. (152) used shRNA libraries to
identify TSG101, a component of the ESCRT machinery,
as having a key role in the uptake and intracellular traf-
ficking of oligonucleotides. Silencing of this gene led to a
dramatic increase in the effectiveness of an antisense antag-
onist of miR-21. This publication establishes two critically
important points. First, that the endomembrane trafficking
machinery plays a key role in the pharmacology of oligonu-
cleotides, and second that the machinery can be manipu-
lated so as to improve oligonucleotide delivery and actions.
Thus, the complex and dynamic pathways of intracellular
trafficking are regulated by an equally complex set of pro-
teins whose interactions vary in time and space throughout
the process. While this makes the investigation of subcel-
lular trafficking rather complicated it also opens up many
opportunities to manipulate the machinery of trafficking
using molecular and chemical probes. As shown by Wage-
naar et al., this can have important implications for oligonu-
cleotide pharmacology. Thus increasing understanding of
the mechanistic basis of oligonucleotide trafficking will
no doubt provide important new avenues to manipulate
oligonucleotide delivery.
Breaching the endosomal barrier. While the trafficking
machinery is usually quite efficient in moving internal-
ized material to the appropriate intracellular destination,
nonetheless opportunities for molecules to escape from en-
domembrane compartments to the cytosol do exist. Traf-
ficking involves a plethora of membrane fusion and fission
events. These events create localized membrane stress that
can result in the formation of non-bilayer lipid domains
(153). Typically non-bilayer regions can be much more per-
meable to solutes than bilayer regions (154,155). Thus there
is an inherent relationship between the fusion/fission events
essential to intracellular trafficking and the potential for
leakage of vesicle contents. There are several loci in the
intracellular trafficking network that may be particularly
susceptible to increases in permeability that would allow
release of oligonucleotides to the cytosol. The first is in
early/sorting endosomes where there is extensive tubula-
tion and formation of vesicles for return of receptors to the
plasma membrane. A second locus is in LE/MVBs where
the ESCRT complex distorts the endosome membrane to
form ILVs. Third, retrograde traffic from early or LEs to
trans-Golgi offers another possibility for membrane insta-
bility. Finally, SNARE driven membrane fusions at multi-
ple sites afford opportunities for partial leakage of vesic-
ular contents (156). The role of specific trafficking events
in oligonucleotide delivery can be explored using molecu-
lar techniques such as siRNA or vectors expressing domi-
nant negative proteins to perturb these events. Another in-
teresting approach is to use cell lines with defects in traf-
ficking processes. There are a growing number of exam-
ples of both approaches in the oligonucleotide literature
(127,152,157,158). In addition to endogenous escape of
oligonucleotides from endosomes, a substantial portion of
the recent literature on oligonucleotide delivery is focused
on approaches to disrupt or alter the endosomal barrier.
Thus cationic lipids and polymers have been used to desta-
bilize the endosomemembrane. Titratable peptides or poly-
mers have been used to alter intra-endosomal pH thus af-
fecting endosome stability and trafficking. Recently a vari-
ety of small molecules have emerged that seem to assist in
endocytosis of oligonucleotides or that selectively perme-
abilize endosomal compartments leading to oligonucleotide
release to the cytosol. It is important to note that once an-
ionic single stranded oligonucleotides reach the cytosol they
readily enter the nucleus (159,160).
APPROACHES TO DELIVERY
This section will examine the recent literature on oligonu-
cleotide delivery. Since hundreds of publications on this
topic appear yearly there is no attempt to provide a com-
prehensive account. Rather, after introducing the topic, the
focus will be on reports that (i) provide insights into basic
mechanisms of oligonucleotide uptake and trafficking, (ii)
utilize novel approaches or (iii) seem unusually promising
at the pre-clinical or clinical levels.
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There are two broad strategies for oligonucleotide deliv-
ery. One is to incorporate the oligonucleotide into some
form of nanocarrier that then determines the tissue dis-
tribution and cellular interactions of the oligonucleotide.
The other is to chemically modify the oligonucleotide it-
self, most commonly with a targeting ligand, while preserv-
ing the molecular nature of the conjugate. A fundamental
difference between the two approaches lies in the size of
the delivery moiety, nanoscale versus molecular scale; this
has profound effects on the biodistribution and biological
actions of the oligonucleotide. Several of the delivery ap-
proaches that will be discussed in detail below are depicted
in Figure 3.
Delivery at the nanoscale
Lipid nanoparticles. The delivery approach that is both
most widely used and most clinically advanced is to com-
plex anionic oligonucleotides with cationic lipids thus form-
ing lipid nanoparticles (LNPs)(161–163). This approach
has been especially important for therapeutic use of siRNA
(164) and good accounts of current clinical trials using
siRNA LNPs are found in recent reviews (10,165). In ad-
dition to the cationic lipid, LNPs typically include a neu-
tral lipid such as cholesterol, but a variety of compositions
are possible. While simple LNPs are effective as cell cul-
ture transfection agents, they cannot be used in vivo be-
cause extensive interactions with opsonic proteins in blood
lead to rapid clearance by RES phagocytes. LNPs for in
vivo use are usually 100–200 nm in size and include a sur-
face coating of a neutral polymer such as PEG to mini-
mize protein binding and uptake by RES cells. This allows
greater persistence in the circulation and the opportunity
to interact with other cell types. However, because of their
size, LNPs can only exit the circulation at sites where the
endothelial barrier is fenestrated, particularly liver, spleen
and certain tumors having a high EPR effect. Because of
this, much of the work with siRNA-LNPs has focused on
liver diseases including transthyrethrin-mediated amyloido-
sis, clotting disorders, liver cancer and disorders of lipid
metabolism (11,166).
The action of LNPs involves initial uptake by endocy-
tosis. In some cases this is mediated by the binding of
apolipoprotein E and interaction with the LDL receptor
(167). Once in endosomes, the cationic lipids of the LNP in-
teract with anionic membrane lipids to disrupt membrane
structure through the formation of a non-bilayer lipid phase
termed inverted hexagonal (HII). This leads both to in-
creased membrane permeability and to dissolution of the
LNP and is the basis for conveying the oligonucleotide to
the cytosol (168). However, the interaction of cationic lipids
with cellular membranes is also the basis for possible toxic-
ities of LNPs (169,170).
A great deal of effort has been expended on optimizing
the delivery properties of LNPs. One problem concerns the
PEG coating (which is usually attached to the LNP by a
lipid anchor). A dense coat is beneficial for increasing cir-
culation time, but it also reduces uptake by cells such as
the hepatocytes that are the intended destination of the
oligonucleotide. Several approaches have been tried to at-
tain dynamic control of PEG levels, including use of cleav-
able linkers or short lipid anchors, with the intent of main-
taining a dense coating of PEG in the circulation while al-
lowing release in the cellular environment (161). Studies of
how PEG density and characteristics affect the pharma-
cokinetics, biodistribution and function of LNPs remains
an active area of investigation (171).
There has also been progress in optimizing the delivery
characteristics of the cationic lipids themselves. A widely
used type of nanocarrier for siRNA delivery is the SNALP
(stable-nucleic-acid lipid particle), a PEG stabilized LNP.
Two important steps for optimizing the cationic lipids were
(i) altering the pKa so that the lipids were almost uncharged
in the circulation but became charged in the low pH endo-
some and (ii) using linkages that were readily biodegrad-
able (172,173). This resulted in dramatic improvement in
effectiveness, allowing siRNA doses as low as 0.005 mg/kg
to achieve significant silencing of hepatic targets in ani-
mal models, accompanied by low toxicity (174). Additional
work on the chemistry of lipids continues. One powerful ap-
proach is the testing of chemical libraries of ‘lipoids’ (lipid
like molecules) for their delivery capabilities (175). Another
interesting strategy is the design of multifunctional lipids
that include a pH responsive head group and well as SH
moieties. The multifunctional LNPs provide increased sta-
bility in the blood but then promote endosome escape in
the low pH and reducing environment of the cell interior
(176). Another approach that may avoid some of the toxi-
cities of cationic LNPs involves using siRNA entrapped in
neutral liposomes (165,177). There has also beenmanipula-
tion of the physical structure of lipid delivery systems. Thus
‘cuboplexes’ are novel lipid structures designed to promote
interaction with endosome membranes and thus allow es-
cape of siRNA to the cytosol (178). Another interesting ap-
proach uses liposomes termed ‘Smarticles R©’ made from
dialkyl cationic amino acids; these undergo a pH sensitive
conversion to a HII phase in endosomes allowing oligonu-
cleotide escape (179).
The precise mechanisms of uptake, intracellular traffick-
ing and ultimate delivery of oligonucleotides by LNPs has
been a matter of some debate (157,180). However, two arti-
cles appearing simultaneously in 2013 used advanced imag-
ing techniques to provide unprecedented insights into the
intracellular fates of siRNA LNPs. Thus Gilleron et al.
(181) found that LNPs were initially taken up by clathrin-
mediated endocytosis but further accumulation involved
macropinocytosis. The LNPs accumulated in an EE-LE
hybrid compartment; however, only 1–2% of the siRNA
reached the cytosol. Sahay et al. (158) also demonstrated a
role for macropinocytosis. However, they found that much
of the siRNA was re-exported from LEs/lysosomes using
a process involving the NPC1 lipid transporter protein. A
more recent study using highly sensitive fluorescence mi-
croscopy techniques documented release of siRNA from
individual endosomes (182). Release took place primarily
at the EE/LE conversion step rather than from lysosomes.
These studies provide important insights into the mecha-
nistic basis of oligonucleotide delivery via LNPs and attest
to the overall inefficiency and transience of oligonucleotide
delivery even when using effective nanocarrier systems.
An important issue is whether it is possible to target
LNPs to particular cells or tissues. An obvious approach











Figure 3. Oligonucleotide delivery strategies. Several approaches to oligonucleotide delivery are depicted. (A) Antibody-oligonucleotide conjugate. (B)
Polymer-oligonucleotide conjugate with PEGylation and targeting ligand. (C)Molecular scale ligand-oligonucleotide conjugate with triantennary carbohy-
drate ligand. (D) Lipid nanoparticle with PEGylation. (E) Gold nanoparticle with dense oligonucleotide coat. (F) DNAnanostructure with oligonucleotide
and targeting ligand incorporated. Images are not to scale.
is to decorate the LNP surface with antibodies. However,
long experience with targeting of drug-loaded liposomes
suggests that it is quite difficult to find the right balance be-
tween PEG shielding and availability of the antibody (183).
Recently however, there have been some interesting reports
using antibody-targeted siRNA LNPs. Thus a scFv was
used to target LNPs to dendritic cells in vivo. Good ‘knock
down’ of several co-stimulatory surface antigens and inhi-
bition of mixed lymphocyte reactions were observed (184).
In another study LNPs decorated with antibody to CD20
delivered Bcl-2 ASO to B-cell tumors in vivo with good an-
titumor effect (185). Additionally an anti CD4 monoclonal
was used to target siRNA LNPs to CD4 positive T-cells re-
sulting in knock-down of the intended mRNAs both in cell
culture and in vivo (186).
Progress has also beenmade using small molecule ligands
to target LNPs. For example, in a series of publications,
Huang et al. have used anisamide as a ligand to assist in
the delivery of siRNA LNPs to tumors (187,188). Finally
aptamers are also being explored as a targeted delivery ap-
proach for LNPs (189). Some of the above mentioned stud-
ies on LNP targeting are also of interest because they in-
volve delivery of oligonucleotides to non-hepatic sites.
Finally, there have been some impressive recent pre-
clinical studies using LNPs. Thus LNPs prepared using
a novel lipid from a chemical library selectively delivered
oligonucleotides to the lung. When used with si-KRAS and
miR-34a, significant inhibition of lung cancer was attained
in a genetically engineeredmouse tumormodel (190). In an-
other study, siRNA LNPs showed therapeutic efficacy ver-
sus Marburg virus (an Ebola relative) in non-human pri-
mates (191). These studies are both good examples of non-
hepatic delivery using LNPs.
In summary, over the last few years there have been im-
pressive advances in the LNP delivery technology. Current
formulations allow highly effective delivery of siRNA to
hepatocytes using doses of oligonucleotide and of lipid car-
rier that display only minimal toxicity. This has allowed sev-
eral liver-based diseases to be addressed. The greater chal-
lenge lies with non-hepatic delivery. Although there have
been some interesting reports using LNPs to deliver siRNA
to other tissues and to tumors, there remain questions re-
garding efficacy and toxicity particularly in the context of
long term use in human therapy.
Polymeric nanocarriers. Various types of polymeric
nanoparticles provide another widely used strategy for
oligonucleotide delivery. Although they have not pro-
gressed clinically to the same degree as LNPs, it is worth
noting that the first use of siRNA to treat human cancer
involved a ligand-targeted cyclodextrin-based polymeric
nanoparticle (192). Excellent recent reviews provide com-
prehensive accounts of the numerous publications utilizing
this general approach to oligonucleotide delivery (193,194).
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There are several types of polymeric nanocarriers. Early
studies in this area primarily usedwell-known, biomedically
compatible polymers such as poly (lactic-co-glycolic acid)
(PLGA) to form solid nanoparticles through various oil-
in-water emulsion techniques. However, since PLGA is an-
ionic, a common approach was to incorporate positive side
chains in the polymer or to complex the anionic oligonu-
cleotide with a positively charged moiety such as polyethy-
lene imine (PEI) (195,196). Polymeric micelles, sometimes
called ‘core-shell’ nanoparticles, have also been widely used
for oligonucleotide delivery. These are formed by self-
assembly of amphiphilic polymers in a water environment.
Typically a tri-block polymer might be used, including a
hydrophobic portion to drive self-assembly, a cationic por-
tion to bind the oligonucleotide and PEG or other neutral
polymer to provide a protective coating (197,198). A recent
report described a novel self-assembled hybrid nanocarrier
comprised of a PLGA core and a lipid-PEG shell. This sys-
tem provided impressive results in terms of a long circula-
tion lifetime and functionally effective delivery of siRNA to
tumor xenografts in mice (199). A third type of polymeric
nanocarrier is the nanohydrogel. These nanoparticles have
an open, water-filled polymer lattice that can easily incorpo-
rate bio-macromolecules such as polypeptides and oligonu-
cleotides, whose release kinetics can be controlled by the de-
gree of cross linking of the lattice. A particularly interest-
ing form is the PRINT nanohydrogel whose size and shape
can be precisely controlled by a nano-molding technique
(200,201). A virtue of many polymeric nanocarriers is their
ready ability to convey both an oligonucleotide and a small
molecule drug; this is especially interesting in the context of
cancer chemotherapy. Thus there are several promising re-
ports of in vivo co-delivery of siRNA and anticancer drugs
(194,197,198).
Another common approach involves the direct complex-
ation of anionic oligonucleotides with cationic molecules
that have some degree of endosome escape capability in-
herent in their chemistry. This would include formation
of nanoscale polyplexes involving CPPs (202,203), cationic
dendrimers such as PAMAMs (194,204) or linear or cross-
linked PEI (205).
CPPs have been extensively studied for oligonucleotide
delivery (74,206). Starting with the original Transactivator
of Transcription (TAT) and penetratin structures, a wide
variety of short polycationic CPPs have been synthesized
and used as delivery agents for drugs, peptides, proteins and
nucleic acids (203,207). In many cases short amphipathic
sequences are also included with the intent of promoting
endosome escape. While some work has been done with
chemical conjugation of CPPs to anionic oligonucleotides,
in most cases delivery is via formation of nanocomplexes.
These are usually in the 100–200 nm range with a surface
charge that depends on the chemistry of the CPP and the
ratio of cationic peptide to oligonucleotide. Perhaps the
most advanced CPP for oligonucleotide delivery remains
PepFect6 that has been used to deliver siRNA in an ani-
mal model resulting in ‘knock down’ of target gene expres-
sion in several tissues (208). Additional work on this type
of CPP has included the incorporation of endosome dis-
rupting moieties such as quinoline derivatives (209). An-
other promising study used a cationic peptide derived from
bee melittin to form nanocomplexes with siRNA directed
against NF-kB; these were used to treat a mouse model of
rheumatoid arthritis (210). In addition to their direct use as
polyplexes, CPPs have been used to augment the properties
of other delivery systems such as LNPs (211). An interesting
variant of the CPP approach entailed making a chimera of
an RNA binding protein and a CPP. This entity could bind
and deliver siRNA in cell culture and in an animal model
(212).
Dendrimers are branched polymers with well-defined ar-
chitectures. By controlling the degree of branching, differ-
ent ‘generations’ of dendrimer can be made thus varying
size and the number of potentially reactive surface moi-
eties. PAMAMs (213), the dendrimer type most commonly
used for oligonucleotide delivery, shares with PEI the abil-
ity to exert a strong ‘proton sponge’ effect. Thus the titrat-
able amines on the PAMAM bind protons in endosomes
and lysosomes leading to increased pumping of protons
by the membrane V-ATPase; this is accompanied by Cl−
transport, water accumulation and swelling and rupture of
the organelle. This makes PAMAM dendrimers very effec-
tive agents for nucleic acid delivery (204). Unfortunately
the strength of the protein sponge effect, along with lack
of biodegradability and multiple non-specific interactions
with blood and tissue proteins, all contribute to the substan-
tial toxicities observed with in vivo use of PAMAMs (214).
By virtue of their multiple surface amino groups PAMAMs
are easily conjugated to a variety of ligands. For example,
PEG has been used to reduce toxicity and improve in vivo
biodistribution properties (215). It is also possible to simul-
taneously conjugate both targeting ligands and therapeuti-
cally active small molecules to PAMAM dendrimers (216).
Thus there is a great deal of flexibility inherent in this deliv-
ery system but concerns remain about toxicity.
PEIs are linear or branched polymers that have multi-
ple titratable amino groups. Thus they can readily form
nanocomplexes with oligonucleotides (217). Like PAMAM
dendrimers, PEI exerts a strong ‘proton sponge’ effect mak-
ing it quite effective for nucleic acid delivery. It is also read-
ily modified by conjugation with a variety of ligands. For
example, a branched PEI modified with PEG and Arg-Gly-
Asp (RGD) ligands was used to deliver siRNA to tumors
in mice (218). In addition to its direct use as an oligonu-
cleotide carrier, as noted above, PEI is often incorporated
into other types of nanoparticles to provide binding for
oligonucleotides and as an endosome escape agent. Unfor-
tunately, PEIs are poorly biodegradable.
There has been a great deal of interest in methods for
targeting nanoparticles with a plethora of research publi-
cations and multiple reviews on this broad topic (219–221).
Recent reviews have focused particularly on siRNA or ASO
delivery using targeted polymeric nanocarriers (222,223).
A widely used approach has been to couple folate to the
nanocarrier surface to promote interaction with cancer cells
that overexpress the folate receptor (224,225). However, al-
though the first demonstrated siRNA effects in man in-
volved a targeted polymeric nanocarrier (192), there has
been little further clinical progress with this approach.
Despite the popularity of polymeric nanoparticles with
pharmaceutical scientists, there is relatively little informa-
tion available about their mechanism of delivery at the cel-
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lular level. A recent study showed that the cellular uptake of
CPP/oligonucleotide nanocomplexes involves scavenger re-
ceptors (226). Another interesting report demonstrated that
theNPC1 lipid transport system, previously shown to be in-
volved in LNP processing (158), is also involved in the pro-
cessing of certain types of polymeric nanoparticles (227).
However, a reduction inNPC1 levels had the opposite effect
on delivery of siRNA using polymers as in the case of de-
livery using lipids. There have been only a few comparisons
of uptake mechanisms for LNPs and polyplexes (157,228);
both of the cited reports suggest that the mechanisms of up-
take are different and one report indicated that polyplexes
are released from endosomes via a rapid bursting process. A
recent study sought to incorporate endosome-disruptive he-
lical peptides into siRNA nanoparticles and demonstrated
release into the cytosol; this systemwas used to knock down
TNF- in an animal model of inflammation (229).
In contrast to the lack of information at the cellular
level, there is substantial data on the pharmacokinetics
and biodistribution of polymeric nanoparticles (193,230).
In mice, as well as in patients, polymeric nanoparticles tend
to be cleared quickly (231) with accumulation in the liver
predominating (232,233). However, as mentioned above, a
recent study with a novel polymeric nanoparticle formula-
tion demonstrated an extended lifetime in circulation and
impressively high levels of tumor uptake as compared to
liver uptake (199). Thus it may be possible to substan-
tially improve the biodistribution characteristics of poly-
meric nanoparticles. Nonetheless, polymeric nanoparticles
have not yet advanced as far as LNPs in terms of pre-clinical
and clinical development.
An interesting offshoot for polymeric nanoparticles in-
volves siRNA delivery via the gastrointestinal tract. Thus
siRNA nanoparticles have been used orally to block inflam-
matory effects mediated by TNF- (234), or have been ad-
ministered into the colon to knock down apolipoprotein B
mRNA (235), or via the rectum to suppress inflammatory
cytokines (236).
Advantages and liabilities of nanoscale delivery. There is
an interesting divergence in the oligonucleotide therapeu-
tics field in terms of approaches to delivery of single strand
molecules and of siRNA or miRNA. For the most part de-
livery of ASOs and SSOs, at least at the clinical level, has
relied on ‘free’ oligonucleotides. By contrast, with one ma-
jor exception, siRNA delivery has relied on nanocarriers,
particularly SNALPS. The reasons for this divergence are
easy to understand. ASOs and SSOs can readily be chemi-
callymodified to resist nuclease degradation and, in the case
of phosphorothioates, they have a long circulation lifetime
and are readily taken up by cells. By contrast, early ver-
sions of siRNA had none of these advantages; they were
very unstable, rapidly cleared by the kidney, and poorly ac-
cumulated by cells. Based on these problems, a huge ef-
fort has gone into the development of siRNA nanocarri-
ers. Although a bewildering variety of lipids and polymers
have been tried, they almost all share the weakness of being
positively charged and therefor highly interactive with an-
ionic biological macromolecules and cells. This inevitably
leads to toxicity especially upon chronic use. As discussed
above, extensive work on the lipid components of SNALPs
has both increased their efficacy for siRNA delivery and
reduced their toxicity. Thus SNALP siRNA formulations
seem a sound approach for siRNA delivery to the liver. It is
not clear that the same can be said about the various types
of polymeric nanoparticles. Although attempts have been
made to reduce the toxicity of dendrimers, PEI or cationic
peptides it is difficult to avoid this entirely because of their
inherent chemical nature.
A potential advantage of nanocarrier systems is that a
large bolus of oligonucleotide can be delivered during one
cellular uptake event. However, the converse is that entry of
a nanoparticle into the cells entails the delivery of a large
mass of carrier material. Even with the best nanocarriers
only a few percent of the total mass is siRNA with the rest
being carrier (172). Thus nanoparticle delivery is inevitably
associated with the accumulation of substantial amounts
of potentially toxic material; this is especially problematic
for lipids or polymers that are not readily biodegradable.
It seems unlikely that such materials will ever be clinically
useful.
A final concern regarding nanocarriers involves their lim-
ited biodistribution. As mentioned early in this review, typ-
ical nanoparticles with diameters of ∼100 nm are excluded
from most tissues by the barrier presented by the capillary
endothelium. Accumulation occurs primarily in liver and
spleen where the endothelium is fenestrated, and to a lesser
degree in certain rapidly growing tumors that have a strong
EPR effect. The parenchyma of most other normal tissues
are virtually inaccessible, thus limiting the range of thera-
peutic applications for nanocarriers.
Delivery at the molecular scale: ligand-oligonucleotide conju-
gates
Partly because of the many concerns about using nanopar-
ticle delivery systems, there has recently been a surge of in-
terest in molecular scale ligand-oligonucleotide conjugates.
These offer the possibility of selective delivery to specific
cells or tissues via receptor mediated mechanisms coupled
with an avoidance of the toxicities often associated with
nanocarriers. Another advantage of conjugates is that they
are well-defined molecular entities as opposed to the het-
erogeneity characteristic of nanoparticles. Thus while the
conjugate approach is still in its infancy, it seems to offer
a promising path forward for oligonucleotide therapeutics.
Conjugation chemistries. There are numerous synthetic
paths for the preparation of oligonucleotide conjugates, as
discussed at length in recent reviews (237–240). Nonethe-
less there are two basic strategies for oligonucleotide con-
jugation. The first is an all solid-phase approach where the
oligonucleotide and ligand are linked while attached to a
support. The other is to couple the two components while
in solution. There are advantages and limitations with both
approaches. Solid phase synthesis is highly efficient and fa-
cilitates purification. However, the availability of compat-
ible synthons and coupling reagents for both the oligonu-
cleotide and the ligand is often a limitation. Another issue
is the need for both ligand and oligonucleotide to be sta-
ble under the conditions of synthesis. By contrast, solution
phase conjugation initially pursues synthesis of each com-
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ponent under the most efficient conditions followed by the
conjugation reaction. However, that reaction may be inef-
ficient and significant post-synthesis purification problems
may exist. Various groups have utilized both strategies for
conjugation, with themajority preferring solution phase ap-
proaches.
There aremany possible linkages for oligonucleotide con-
jugates. Recently there has been much interest in using
‘click’ chemistry since the reactants do not cross-react with
common biomolecules and the process is quick and efficient
(240–243). However, the bond formed is not bioreversible.
More traditional linkages include disulfide bridges and pH
sensitive ester linkages that provide reversibility within the
cell (240). The issue of reversibility can be an important one
depending on the choice of ligand. For smaller ligands such
as short peptides or small organic molecules our experience
(244) as well as that of others (245) indicates that both re-
versible and non-reversible linkages permit biological activ-
ity of the oligonucleotide. However, for larger ligands such
as proteins or polymers reversibility is likely to be more im-
portant.
Non-targeted conjugates. Much of the early work on
oligonucleotide conjugates involved ligands that were de-
signed to promote cell uptake but lacked specificity. The
most notable examples are lipid conjugates and CPP con-
jugates.
Lipid conjugates. One of the earliest successes in enhanc-
ing the delivery of siRNA was through conjugation of the
oligonucleotide with cholesterol (246). This significantly
promoted uptake by the liver and enabled silencing of hep-
atic genes. Similar effects were seen with other lipidic con-
jugates including -tocopherol and long chain fatty acids
(247,248). The cholesterol conjugates associated with serum
lipoproteins thus facilitating uptake via lipoprotein recep-
tors. Although this approachwas a pioneering one it faced a
number of difficulties including the need for relatively large
doses to attain efficacy. Thus much of the effort in hepatic
delivery has switched to SNALPs or to other types of con-
jugates.
CPP conjugates. As mentioned above, nanocomplexes of
CPPs with anionic oligonucleotides have been widely eval-
uated as delivery vehicles. However, molecular scale chem-
ical conjugates of CPPs with uncharged oligonucleotides
such as PMOs and PNAs have also shown promise. By far
the most extensively studied conjugates involve a variety of
CPPs linked to PMO SSOs designed to correct the defec-
tive production of dystrophin that is the basis of Duchenne
muscular dystrophy. Much of this work was recently re-
viewed in detail (74) and only a brief summary is provided
here. The CPPs used in these studies contain tracts of argi-
nine residues interrupted by short hydrophobic sequences.
A large number of variants have been tested thus permit-
ting structure activity relationship studies. The CPPs are
usually coupled via their COOH terminal to the 3′ end of
the PMO, but other configurations are possible. Using the
mdxmouse model of muscular dystrophy, strong splice cor-
rection and upregulation of dystrophin expression in mus-
cle was seen with several conjugates. Recent versions have
also increased dystrophin expression in heart, which is a
particularly challenging problem. Other studies include at-
tempts at combining CPPs with targeting peptides derived
from phage display so as to increase specificity of delivery.
Another interesting variation has been to couple two differ-
ent oligonucleotides to a single CPP thus addressing two
targets at the same time (243). Although the mechanism
of delivery of the CPP-PMOs is not entirely clear, recent
studies have investigated their subcellular behavior. Inter-
estingly the same CPP-PMO conjugate displayed different
uptake and trafficking processes in cultures of skeletal mus-
cle cells versus cardiomyocytes, with uptake and nuclear de-
livery of the PMO-SSO correlating with biological effect
(249). Another interesting study found that CPP-PMO con-
jugates, as well as tricyclo oligonucleotides, tend to sponta-
neously form nanoparticles whose uptake was then medi-
ated by scavenger receptors of the SCARA 1 class (61).
In addition to studies in the context of muscular dys-
trophy, CPP-PMO conjugates have also been explored for
anti-viral and anti bacterial properties (250,251). However,
this thrust has been supplanted by the use of PMOs having
positive piperazine residues incorporated into the backbone
(252,253); these seem to be less toxic than the CPP-PMOs
in the antiviral context and have shown impressive results
in trials against Marburg virus in monkeys and were appar-
ently well tolerated in phase I trials in man (254).
Targeted conjugates. The last couple of years have seen a
major shift of emphasis in the oligonucleotide therapeutics
area away from lipid or polymer based nanocarriers and to-
ward targeted molecular- or macromolecular-scale conju-
gates. Thus far the greatest successes have come in delivery
to the liver but interesting reports of extra hepatic targeting
have also appeared. The sections below recapitulate some
of the most important developments in this rapidly grow-
ing area; several recent reviews have also dealt with targeted
conjugates (240,255,256).
Glycoconjugates: the asialoglycoprotein receptor. Themost
dramatic advance in oligonucleotide targeting has involved
delivery via the ASGR. As mentioned above, this re-
ceptor is almost ideal for targeted delivery to the liver,
combining tissue specificity, high expression levels and
rapid internalization and turnover. Additionally, there ex-
ists a deep background on the chemistry of oligonu-
cleotide glycoconjugates that has facilitated progress in this
area (257). A major breakthrough came from researchers
at Alnylam Pharmaceuticals who developed multivalent
N-acetylgalactosamine (GalNac) conjugated siRNAs that
bind at nanomolar levels to the ASGR (258). A synthetic
scheme was devised that allowed direct solid phase synthe-
sis of the conjugates. The siRNAs used were heavily chem-
ically modified to enhance their in vivo stability. The conju-
gates were effectively taken up into primary mouse hepato-
cytes by a receptor-specific mechanism, leading to silencing
of targeted genes. Similarly, using a radiolabeled conjugate,
excellent uptake into liver was observed in mice; interest-
ingly higher levels were obtained by subcutaneous adminis-
tration rather than intravenous administration. Conjugates
addressing the transthyretin gene effectively reduced expres-
sion, with subcutaneous administration being superior to
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intravenous thus paralleling the uptake studies. Chronic
dosing resulted in gene silencing for over 9 months with no
adverse effects apparent. This study highlighted several of
the virtues of conjugates including use of a molecularly de-
fined entity, high tissue and cell selectivity, the ability to use
the subcutaneous route, and lack of substantial toxicity. Al-
though the siRNA doses required were higher than those
needed for advanced SNALP systems, nonetheless the ad-
vantages of the conjugate approach seem clear.
There have been a number of other studies of ASGR-
mediated delivery. The Alnylam group has further opti-
mized the chemistry of the glycoconjugates, providing sim-
pler alternatives for synthesis (259,260). Multivalent glyco-
conjugates have also been used to target novel uncharged
siRNA entities (47) with the attainment of similar func-
tional effects in cells and in vivo. GalNac based conjugates
have also been used to deliver ASOs to the liver in mice
with good effects on reduction of target gene expression
(261). However, since in contrast to siRNAs, the unmodi-
fied ASOs also accumulate efficiently in liver, the fold en-
hancement observed for GalNac conjugated ASOs was not
as great as that described for siRNAs. This exciting tech-
nology has elicited the interest of many groups and vari-
ous publications on the chemistry and biology of GalNac
oligonucleotide conjugates are starting to appear (262–264).
The successes with glycoconjugates in the laboratory
have facilitated their rapid translation to clinical evalua-
tion, with several hepatic genes being addressed. Thus a
GalNac-siRNA conjugate for therapy of transthyretin me-
diated amyloidotic cardiomyopathy is now in Phase 3. Ad-
ditionally, Phase 1 or 2 studies are currently in progress for
siRNA glycoconjugates addressing hemophilia A or B, an-
titrypsin deficiency and porphyria (Clinical Trials.Gov)(5).
While the long-term effectiveness and toxicity of siRNA
glycoconjugates remain to be determined, at the present
moment this approach seems to offer the most promising
avenue for targeted oligonucleotide delivery to the liver.
Peptides. There have been a number of studies with
peptide-oligonucleotide conjugates designed to bind to spe-
cific cell surface receptors. Much of the activity has fo-
cused on cyclic Arg-Gly-Asp (RGD) or other integrin lig-
ands; these have been widely studied in connection with
nanoparticle delivery (265) but there are only a limited num-
ber of studies of such ligands with conjugates. An early
study demonstrated the feasibility of using RGD ligands
to increase the cellular uptake and effectiveness of a SSO
(244). In another report mono-, bi- tri- and tetra-valent
RGD siRNA conjugates were tested in cell culture (266).
Interestingly the tri- and tetra-valent conjugates provided
stronger silencing than the other conjugates even under con-
ditions where cell uptake was comparable. This suggests
that valency may affect the intracellular trafficking of the
conjugate in a manner that impinges on effectiveness. The
most complete study with RGD ligands involved chemi-
cally modified siRNA directed against VEGF-Receptor 2
and conjugated to a PEG-RGD (267). Since VEGF is es-
sential for tumor angiogenesis and since RGD is primarily
a ligand for the alphavbeta3 integrin that is overexpressed in
angiogenic endothelial cells, this combination seemed well
suited to inhibit rapidly growing tumors. The RGD-siRNA
conjugates were taken up by cultured endothelial cells via
a receptor specific mechanism and reduced VEGF-R2 ex-
pression. In tumor bearing mice repeated dosing resulted in
a modest reduction in VEGF-R2 expression but a signifi-
cant reduction in tumor growth. No toxicity was apparent
in these studies. Although the in vivo results were only par-
tial it should be noted that the doses used (∼0.7 mg/kg)
were rather low as compared to, for example, the doses of
the GalNac conjugates described above.
A variety of other peptide ligands and their cognate
receptors have been used for targeting. For example, the
gastrin-releasing peptide receptor, a member of the GPCR
superfamily, has been utilized to enhance delivery of a SSO
(268) or a siRNA (269), both in cell culture. A later study
used multivalent hybrid peptides that included the target-
ing sequence as well as several histidine residues designed
to promote endosome destabilization via the proton sponge
mechanism; however, the inclusion of the histidine pro-
duced only a modest improvement (270). Ligands target-
ing the gastrin-releasing peptide receptor have been exten-
sively used in vivo for delivery of imaging agents and drugs
(271) but such in vivo studies have not yet been done with
oligonucleotides. Another study used an siRNA conjugate
of insulin-like growth factor 1 for delivery in cultured cells
(272), but this has not yet been followed up. Thus, at present,
in vivo studies with molecular scale peptide-oligonucleotide
conjugates lag far behind those with glycoconjugates. It is
possible that this may indicate that there have been a num-
ber of unreported failures with this approach; however, it
is also possible that determined efforts have not yet been
made.
Aptamers and other oligonucleotides. Nucleic acid ap-
tamers offer one of the most promising tools for tar-
geted oligonucleotide delivery (273). Aptamers are nucleic
acids that form three-dimensional (3D) structures via intra-
molecular base pairing.Using thewell-known SELEX tech-
nique, aptamers can be selected to bind to virtually any
receptor with nanomolar to picomolar affinities (274). Al-
though aptamers are usually generated by in vitro transcrip-
tion and are many tens of bases in length, in some cases
they can be redesigned and truncated so as to permit their
production by solid phase chemical synthesis. This allows
very efficient production of chimeras of the aptamer and
the passenger strand of an siRNA, with the guide strand
then added by base pairing. The use of aptamer-siRNA
conjugates was pioneered by Sullenger et al. who described
an aptamer that bound prostate-specific membrane anti-
gen (PSMA) coupled to siRNAs directed toward key pro-
survival genes. This chimera could effectively kill tumor
cells that expressed PSMA but not those that did not. The
chimera also had growth inhibitory effects when injected
directly into the tumor (275). In later studies Giangrande
et al. optimized the PSMA aptamer and conjugated it to
PEG to improve in vivo characteristics (276). The modi-
fied aptamers displayed good antitumor activity at moder-
ate doses and without apparent toxicity in a prostate cancer
xenograft model. Subsequently, there have been a number
of additional studies exploring aptamer-mediated delivery
of siRNA in the cancer context. This includes use of biva-
lent aptamer-siRNA conjugates (277), aptamers that target
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growth receptors in leukemic cells (278), delivery of can-
cer inhibitory miRNAs via aptamers (279,280), as well as
delivery of siRNAs that sensitize cells to chemotherapeu-
tic agents (281). An interesting approach is to use an ap-
tamer that is itself inhibitory to a growth promoting recep-
tor linked an siRNA that also causes growth inhibition, thus
potentially having a dual effect on tumor cells (278,279).
While several of these approaches seem promising, thus far
they have mostly been restricted to studies in cell culture.
A novel approach to use of aptamers in cancer im-
munotherapy was developed by Gilboa et al. Cancer cells
use the nonsense-mediated decay (NMD) pathway to blunt
expression of tumor antigens that might be recognized by
the host immune system. A PMSA aptamer was used to
deliver siRNAs that inhibit the NMD pathway to tumors
thus enhancing the immune response to the tumor and caus-
ing significant inhibition of primary and metastatic tumor
growth (282). More recently this group used a somewhat
similar strategy to stimulate anti-tumor immunity by selec-
tive reduction of mTOR in CD8+ T-cells using a CD8 ap-
tamer linked to an siRNA that silences TORC1, a compo-
nent of the mTOR complex (283). Other investigators have
also successfully used aptamer-siRNA chimeras to regulate
tumor immunity (284)
There has also been a great deal of work on the use of
aptamer-siRNA conjugates in HIV therapeutics with much
of this pioneered by Rossi et al. (285). Thus aptamers that
recognize the viral envelop protein gp120were linked to siR-
NAs targeting viral genes such as tat/rev. These chimeric
molecules afforded significant suppression of HIV in in-
fected cells in culture as well as in HIV infected human-
ized mice (286,287). This group also developed a design ap-
proach that they call the ‘sticky bridge’ that allows facile as-
sembly of siRNAs and aptamers. An interesting offshoot of
work in this area involves using aptamer-siRNA chimeras
to block genital transmission of HIV. This entails use of a
vaginal gel containingCD4-binding aptamers linked to siR-
NAs that target HIV (288).
Although not derived by SELEX, another aptamer-like
chimera involves CpG oligonucleotides linked to siRNAs.
As mentioned above, TLR9 strongly binds to certain types
of unmethylated CpG-rich DNA oligonucleotides. This has
been developed as a strategy for siRNA delivery to nor-
mal and malignant hematopoietic cells (289) and dendritic
cells (290). In the original study CpG oligonucleotides were
chemically coupled to an siRNA targeting Stat3. The con-
jugates were effectively taken up by TLR9 positive cells re-
sulting in silencing of Stat3. Since suppression of Stat 3 is
thought to promote antitumor immunity, the CpG-siStat3
conjugates were tested in vivo and shown to inhibit growth
in several tumor models (291).
Aptamers represent a powerful strategy for the targeted
delivery of oligonucleotides. Nonetheless a decade after the
initiation of this approach aptamer-oligonucleotide con-
jugates or chimeras have not progressed to clinical trials.
There may be several reasons for this. Thus the relatively
large size and complexity of typical RNA aptamers render
them particular susceptible to nuclease degradation. The
substitution of DNA-based aptamers may help with this is-
sue (219). Further, although aptamers can be designed to
bind to virtually any cell surface receptor, not all receptors
effectively deliver cargo to the cell interior. Thus an inter-
esting new development is the evolution of SELEX type ap-
proaches for identifying aptamers that are efficiently inter-
nalized into cells (292,293). In summary, aptamer mediated
delivery of oligonucleotides remains a work in progress with
exciting potential that has yet to be fully realized.
Antibodies. Monoclonal antibodies are potentially a pow-
erful tool for targeting of oligonucleotides. However, it has
become apparent that there are many complexities that will
need to be addressed before this technology is ready for clin-
ical development. Antibody-mediated siRNA delivery was
first described by Lieberman et al. (294). In this study an
immunoglobulin Fab-protamine chimera was created that
targeted the HIV gp160 envelop protein. This was com-
plexed with siRNAs addressed to key viral genes such as
gag and could inhibit HIV in infected T-cells. In tumor
cells ectopically expressing gp160, complexes of the chimera
with siRNAs addressing key growth related genes could in-
hibit tumor cell growth both in culture and in vivo. Similar
studies were also conducted with a scFv-protamine chimera
that targeted the ErbB2 cell surface receptor. Another study
used a scFv-protamine chimera that targeted Her2 to de-
liver growth inhibitory siRNAs to Her2 positive breast can-
cer cells causing retardation of tumor growth in an or-
thotopic breast cancer model (295). Utilizing a similar ap-
proach, another group developed a chemical conjugate of
an anti-CD7 scFV with a positively charged arginine pep-
tide; this was then complexed with anti HIV siRNAs. The
complexes were used to treat HIV infected humanized mice
resulting in alleviation of the disease (296). These initially
promising studies shared a major problem; the antibody–
siRNA complexes formed were probably ill-defined mul-
timeric aggregates rather than defined molecular species.
Thus further pharmaceutical development of these entities
would be difficult.
More recently an extremely thorough study has delin-
eated both the potential and the difficulties associated with
antibody mediated delivery of siRNA (297). The authors
used so-called THIOMABs previously developed for drug-
antibody conjugates. This allowed chemical linkage of siR-
NAs at precisely defined positions on the antibody and re-
sulted in the creation of molecularly defined conjugates.
THIOMABs targeting a number of different cell surface re-
ceptors were tested where the receptors varied in terms of
abundance and routes and rapidity of uptake and intracel-
lular trafficking.While two receptors (TENB2 andNaPi2b)
provided moderate silencing, the others did not. Nonethe-
less, the various THIOMABs and their linked siRNAs all
seemed to accumulate in lysosomes indicating that there
is not a simple correlation between overall subcellular lo-
calization and effect. The TENB2 antibody conjugate was
tested in a mouse tumor model; however much of the ma-
terial only penetrated a short distance from the vascula-
ture. This study highlights several important issues. First,
it is very difficult to identify cell surface receptors that can
efficiently deliver oligonucleotides (although it should be
noted that both of the effective receptors were very abun-
dant). Second, the bulk intracellular trafficking pathways
as visualized by fluorescence microscopy may not be rele-
vant and that minor trafficking pathways may be function-
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ally important. Third, conjugates of intact immunoglobu-
lins with siRNA (∼180 000 MW) may have difficulties pen-
etrating tissues. This study also emphasizes that endosome
escape is a critical aspect of delivery. Thus the antibody-
oligonucleotide delivery area is still evolving. It would be
of great interest to bring the THIOMAB approach to much
smaller protein targeting reagents such as scFvs or various
molecular scaffolds based on DARPINs or fibronectin type
III repeats (298).
Other macromolecular-scale conjugates. A very promising
approach to oligonucleotide delivery involves so-called ‘dy-
namic polyconjugates’ (299). In the original conception
these were comprised of a polymer with inherent endo-
some destabilizing properties linked simultaneously to a
PEG shield, a carbohydrate ligand targeting the ASGPR
and siRNA (300). The PEG linkage was designed to be de-
graded at low pH thus unmasking the polymer within the
endosome; the siRNAwas attached by a reducible disulfide
linkage. These polyconjugates attained effective silence of
genes in hepatocytes in culture and in mouse liver. In a later
version (301) a membrane destabilizing peptide (mellitin
like peptide, MLP) was conjugated to a ligand for ASGPR
and to PEG (via a pH sensitive linker). The siRNAwas con-
jugated to cholesterol thus promoting uptake by lipoprotein
receptors. The concept was that the siRNA and the MLP,
although taken up by different receptors, would both accu-
mulate in an acidic endosome/lysosome compartment thus
unleashing theMLP and causing endosomal destabilization
and siRNA release. This version demonstrated impressive
silencing effects in a mouse model of hepatitis B. The poly-
conjugate approach has progressed rapidly and is now in
clinical trials; as well, new versions are being developed that
may permit non-hepatic targeting (302).
Another form of macromolecular oligonucleotide con-
jugate involves linking oligonucleotides and targeting lig-
ands to a serum protein. For example, RGD-PEG ligands
have been conjugated to albumin, which was then further
conjugated with a SSO via a bioreversible linkage (303). In
another version the SSO was first conjugated to a ligand
(RGD) and then to albumin (304). In both cases there was
efficient receptor-selective delivery of the oligonucleotide
to cells. It is possible to conjugate 10–15 oligonucleotides
to each albumin thus providing a very high load of active
agent. The conjugates are about 12 nm in diameter and
thus should be large enough to avoid renal clearance but
still small enough to penetrate into most tissues. For exam-
ple, a RGD-SSO-albumin conjugate readily penetrated into
a 3D tumor spheroid whereas a conventional nanoparticle
could not (305). While this system does not yet include an
endosome-destabilizing component it should be relatively
easy to incorporate this function. Although still at an early
stage of development, protein based oligonucleotide carri-
ers seem to offer a simple and flexible delivery platform.
Small organic molecule conjugates. The pharmaceutical
industry possesses a vast number of small organic molecule
ligands––drugs or drug candidates––that demonstrate high
affinity and selectivity for various receptors. Nonetheless
there has been only limited progress to date with small
molecule-oligonucleotide conjugates. Anisamide is a ligand
that binds to the sigma receptor. Mono- and multivalent
anisamide-SSO conjugates were synthesized and tested for
biological activity in cells (306). Trivalent but not mono-
valent conjugates provided effective delivery of the SSO.
Anandamide, a ligand for cannabinoid receptors, was con-
jugated to siRNA via click chemistry (242). These conju-
gates provided effective functional delivery of siRNA to sev-
eral cell types. The folate receptor is believed to be upregu-
lated in many types of cancer cells and folate has been ex-
tensively used as a targeting ligand for drugs and nanoparti-
cles (307). A folate-PEG-siRNA conjugate was prepared by
click chemistry (308). However, although efficiently taken
up by cells expressing the folate receptor, the conjugate
failed to achieve knock down of the targeted mRNA un-
less an additional transfection agent was used. Potentially,
small organic ligands offer enormous versatility for selective
delivery of oligonucleotides. However, their use has been
constrained by several problems. First, it is often difficult
to prepare an oligonucleotide conjugate without disrupting
the ability of the small molecule to interact with its recep-
tor. Second, these materials are relatively small in size and
would be rapidly cleared in the kidney. Third, it is difficult
to build endosome-disrupting capabilities into these conju-
gates.
Advantages and liabilities of molecular scale delivery.
Molecular scale ligand-oligonucleotide conjugates offer
several advantages in terms of delivery considerations.
First, they are well-defined molecular entities that can be
precisely characterized by standard techniques such as nu-
clear magnetic resonance and mass spectrometry. This con-
trasts with most nanoparticles that are heterogeneous in
size and comprised of complex mixtures of lipids or poly-
mers. The defined nature of molecular conjugates may be
a key determinant in their future development as phar-
maceutically and clinically acceptable entities. The second
advantage involves their broad biodistribution. Thus, as
with ‘free’ oligonucleotides, conjugates readily pass across
the capillary endothelium and efficiently penetrate tissue
parenchyma. A good example of this is the observation that
intrathecally administered ASOs can diffuse widely in the
brain (68). Once again this contrasts with nanocarriers that
have a much more restricted biodistribution and that may
have difficulty in diffusing through the dense extracellular
matrix of many tissues. A third potential advantage may
be greater selectivity. A single ligand–oligonucleotide conju-
gate can interact with its cognate receptor via a precise ‘key
in lock’ mechanism. By contrast, even liganded nanoparti-
cles may display non-specific binding to cell surfaces unless
the nanoparticle surface is extremely well masked by PE-
Gylation or similar means. To be fair, oligonucleotide con-
jugates can also display non-specific interactions to some
degree. For example, the propensity of phosphorothioates
to promiscuously stick to proteins may blunt the selectiv-
ity of targeted conjugates that use this backbone. Nonethe-
less, this issue seems more daunting for nanoparticle carri-
ers. Finally, because of their relatively simple composition
and lack of high positive charge density, there seems less op-
portunity for conjugates to generate non-specific toxicities
than is the case for typical nanocarriers.
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There are also some disadvantages to molecular scale
oligonucleotide conjugates. A major one is their small size
that allows rapid renal clearance. This can be countered
to some degree by linking a PEG chain to the conjugate
thus increasing its hydrodynamic radius, but nonetheless re-
mains an issue. A second potential problem involves the
‘payload’. When an oligonucleotide-laden nanocarrier is
taken up by a cell, hundreds or thousands of copies of the
oligonucleotide are potentially available. By contrast, each
uptake event of a molecular conjugate conveys only a sin-
gle oligonucleotide; thus, many events are required to ac-
cumulate sufficient oligonucleotide for a pharmacological
effect. In this context, it is interesting to compare effects of
the siRNA glycoconjugates described above with those of
recent types of siRNA LNPs. While both approaches can
effectively silence expression of hepatic genes, the LNP sys-
tem can do so a doses of 0.1 mg/kg as compared to >5
mg/kg for the glycoconjugate (175,259). A final issue con-
cerns stability. Clearly one of the advantages of nanocarriers
is their ability to protect the oligonucleotide load from nu-
cleases; this is less true of conjugates. For conjugates based
on highly stable backbones such as PMOs or LNAs this
is not a great concern; however, even stabilized forms of
siRNA remain somewhat susceptible to nucleases.
Macromolecular scale conjugates occupy a mid ground
between nanocarriers and simple conjugates. Size consider-
ations are very important here. For example, the ‘dynamic
polyconjugates’ described above are designed so as to re-
duce renal clearance but still obtain a broad tissue distri-
bution. Nonetheless size constraints may affect tissue pene-
tration, as was the case for the THIOMAB antibody conju-
gates. Macromolecular conjugates share with nanocarriers
the ability to convey multiple oligonucleotides in a single
uptake event, but may have less toxic potential, particularly
if no polycationic components are used.
In summary then, there are advantages of molecular
or macromolecular scale oligonucleotide conjugates over
nanocarriers that may be critical in certain therapeutic sit-
uations. However, nanocarriers may provide a useful ap-
proach in certain instances, with hepatic delivery being one
important possibility.
Unusual approaches. Here, we discuss three oligonu-
cleotide delivery approaches that are quite different
from the ones mentioned above. Spherical nucleic acids
(SNAs) and DNA nanostructures represent two novel
nanotechnology-based approaches, while exosome-based
delivery utilizes an important endogenous biological mech-
anism.
Spherical nucleic acids (SNAs). Mirkin et al. have devel-
oped novel nanocarriers based on the dense absorbtion
of oligonucleotides to gold nanoparticles via metal-thiol
bonds. In two very thorough studies, SNAs were shown
to be taken up into a variety of cell types by a process
that involves scavenger receptors, caveolae and trafficking
to EEs and LEs, but not lysosomes (309,310). The nucleic
acid is gradually degraded and released from the cell while
the core is not. SNAs have now been evaluated in several
therapeutic contexts (311–313). For example, gold-siRNA
nanoparticles were able to reduce target mRNA expres-
sion in glioblastoma cells in culture. Further, in a glioblas-
toma xenograft model, good distribution of the nanopar-
ticles within the tumor was observed both after local and
systemic administration, suggesting that SNAs can pen-
etrate the tumor-compromised BBB. Finally an SNA di-
rected against a key survival factor for glioblastoma was
effective in reducing tumor growth (311). Interestingly, al-
though anti-tumor effects were seen, the overall biodistri-
bution of SNA was similar to that observed with other
nanoparticles, with liver predominating. SNAs seem to pro-
vide an interesting and flexible technology. It is possible to
adapt these nanoparticles for targeting (314) and to use ma-
terials other than gold as the core (315). A possible major
impediment for this approach is that the SNAs seem to suf-
fer from the same clearance and biodistribution issues as
conventional lipid or polymer nanoparticles. However, fur-
ther manipulation of particle size or of the PEGylation of
the particles may be helpful.
Exosomes. Virtually all cells shed a variety of small mem-
branous vesicles. Exosomes, which are ∼30–100 nm in di-
ameter, represent a particular type of vesicle that is gener-
ated via the ESCRT machinery. Thus the membrane lipid
and protein composition of exosomes closely parallels those
of the LE/MVB compartment. Additionally exosomes con-
tain a sampling of cytosolic small molecules, proteins and
nucleic acids including both mRNAs and miRNAs (316).
Exosomes shed into the extracellular environment can in-
teract with cells in a variety of ways including binding
to and stimulating receptors, transferring membrane lipids
and proteins, and most interestingly in terms of this review,
delivering RNAs (317,318). Because of these multiple in-
teractions there has been a great deal of recent interest in
translational aspects of exosomes for both diagnostic and
therapeutic purposes and a number of clinical trials involv-
ing these vesicles are now underway (ClinTrials.gov). Re-
cent studies have used sophisticated imaging techniques to
document the dynamic exosome-mediated transfer of both
membrane proteins and mRNA between cells thus validat-
ing this concept (319).
Pioneering work on exosome-mediated delivery of
siRNA was initiated by Wood et al. (320). They expressed
a fusion protein of LAMP2b, a LE/lysosome marker, with
a rabies virus peptide sequence that binds the acetylcholine
receptor. Exosomes containing the fusion protein were iso-
lated and then loaded with siRNAs. The exosomes were
efficiently taken up by neuronal cells in culture result-
ing in ‘knockdown’ of the siRNA target. Surprisingly, the
neuronal-targeted exosomes also delivered the siRNA to the
brain causing reduction of the cognate mRNA and protein.
There have been a number of additional studies from vari-
ous groups regarding the delivery of bothmiRNAs and siR-
NAs using exosomes, with promising results obtained both
in cell culture and in vivo (321–323).
Thus exosomes provide an exciting new avenue for deliv-
ery of oligonucleotides. An appealing aspect is the ability to
express chimeric proteins on the exosome membrane thus
directly engineering targeting capabilities into these vesicles.
However, a number of challenges remain. Despite a great
deal of effort (324), the production and characterization of
exosomes remains poorly defined. This is clearly an imped-
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iment to the development of pharmaceutically acceptable
delivery strategies using exosomes.
DNA nanostructures. DNA nanostructures represent an
exciting new avenue for biotechnology research and devel-
opment (325,326). DNA can be organized into precisely
designed two- and 3D structures by hybridization of com-
plementary sequences. Several synthetic strategies are pos-
sible including the ‘DNA origami’ approach wherein long
strands of DNA are structured using short DNA ‘staples’,
as well as other strategies; powerful computational tools
are available to aid in precise design of the intended struc-
tures. Delivery of oligonucleotides is one of the many po-
tential biomedical applications ofDNAnanostructures, but
one that has elicited considerable recent interest. One of
the unique features of DNA nanostructures is that target-
ing capabilities based on nucleic acid aptamers can be di-
rectly incorporated into the nanostructure. In an elegant
example of this approach aptamers were built into a DNA
‘nanobox’. When the aptamers engaged their cognate cel-
lular ligands the box opened to release entrapped contents
(327). Other studies have also used aptamers for the delivery
of DNA nanostructures (328,329). In a similar fashion, an-
tisense or siRNAmolecules can be incorporated into the de-
sign of the nanostructure. One very thorough study created
∼30 nm tetrahedral nanostructures incorporating siRNA
designed to act on luciferase message; the nanostructures
were further conjugated with folate. These entities were ef-
ficiently taken up in cell culture by tumor cells express-
ing folate receptor and could cause reduction of luciferase
mRNA. In vivo the nanostructures were rapidly cleared, but
surprisingly and unlike most nanoparticles, they avoided
capture by the liver. Partial siRNA effects were attained
in a tumor xenograft model (330). In an interesting vari-
ant of the nanostructure approach, rolling circle transcrip-
tionwas used to generateRNAs containingmultiple siRNA
hairpins; these were complexed with short, ligand-modified
DNA oligonucleotides to form nucleic acid nanoparticles
that were active in cells and in vivo (331). An interesting
feature is that stable nanocomplexes were formed in the ab-
sence of any polycationic materials, thus avoiding potential
toxicities. In another interesting approach CpG oligonu-
cleotides were incorporated into DNA nanostructures re-
sulting in enhanced immuno-stimulation of macrophages in
cell culture (332) and in vivo (333).
Certainly DNA nanostructures have exciting potential
for the future. They can be precisely engineered at the
nanoscale, can readily incorporate both functional nucleic
acid sequences as well as aptameric or small molecule tar-
geting ligands, and can potentially be made sufficiently
small (<20 nm) so as to access non-hepatic tissues. How-
ever, to date there is little experience with the in vivo biodis-
tribution and stability properties of these entities. As an-
ionic polymers they would presumably interact with scav-
enger receptors and possibly TLRs thus creating signaling
cascades that may be detrimental.
Small molecules that enhance oligonucleotide effects. An
important new thrust for oligonucleotide therapeutics in-
volves the concept of using small organic molecules to en-
hance the pharmacological effects of antisense and siRNA.
Conceptually small molecules might influence any aspect
of oligonucleotide behavior including cellular uptake, intra-
cellular trafficking, access to the cytosol and nucleus and
the function of the final effectors such as the RISC com-
plex, RNaseH or the splicesosome. However, most of the
molecules discovered to date affect some aspect of oligonu-
cleotide uptake or trafficking.
An early example of this thrust involved a compound
called Retro-1. This compound originated from a high
throughput screen seeking molecules that could block the
actions of certain bacterial and plant toxins that utilize the
retrograde trafficking pathway (334). Although there was
no obvious connection between oligonucleotides and bac-
terial toxins, Retro-1 was tested for its ability to enhance
the effects of oligonucleotides. Somewhat surprisingly this
molecule provided a modest (∼10-fold) augmentation of
SSO and ASO effects in the absence of any conventional
transfection agent (335). Further experiments showed that
the functional effects of Retro-1 were correlated with selec-
tive release of the SSO from the LE compartment. Retro-1
treatment also provided a small enhancement of the in vivo
effects of an SSO in a mouse tumor model. However, there
were some liabilities associated with this compound in that
concentrations near 100 uM were needed and further that
the lipophilicity of the compound made in vivo experiments
difficult. Thus efforts commenced to find compounds supe-
rior to Retro-1.
An unbiased high-throughput screen was developed to
seek oligonucleotide-enhancing compounds. The screen uti-
lized a cell line stably transfected with a luciferase reporter
whose expression could be increased by successful delivery
of an SSO. Approximately 150 000 compounds were tested
(in the absence of conventional transfection agents) lead-
ing to the discovery of three structurally distinct compound
families. The screen and characterization of one family of
compounds have recently been reported (336). One of the
hits from the screen (UNC7938) provided ∼200-fold en-
hancement of SSO effects in cell culture when used at a
non-toxic concentration (10 uM). This molecule could also
substantially enhance the effects of ASOs and siRNA. By
expressing GFP chimeras of proteins that are known mark-
ers of particular endomembrane compartments it was es-
tablished that the functional effects of UNC7938 were cor-
related with selective release of oligonucleotide from LEs,
similar to the case of Retro-1. In an in vivo model us-
ing transgenic mice with an EGFP reporter inducible by
SSOs, significant enhancing effects ofUNC7938were found
in several tissues including heart, kidney and liver. Thus
this report illustrated the possibility of discovering small
molecules that can profoundly enhance the effectiveness of
oligonucleotides both in cell culture and in vivo. Work on
the initial ‘hits’ from this screen is continuing with the goal
of finding analogs with greater potency and less toxicity.
Other groups have also utilized screening of compound li-
braries to seek oligonucleotide enhancing small molecules.
In one study a small library of drug-like molecules was
screened for their effects on a highly modified siRNA in a
dual luciferase reporter system (337). One hit compound,
a known drug called Guanabenz, provided a substantial in-
crease in potency and efficacy of the modified siRNA in cell
culture when used in the 50–80 uM range. In mechanistic
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studies it was determined that Guanabenz increases inter-
nalization; this molecule is positively charged and appar-
ently forms a molecular complex with the siRNA that pro-
motes cellular uptake. Thus the actions of Guanabenz may
be similar to previously reported small cationic molecules
that bind to siRNA and enhance its uptake by cells (338).
Several compounds related to Guanabenz were also ex-
amined to evaluate structure activity relationships. Inter-
estingly, Guanabenz had little effect on forms of oligonu-
cleotide other than the highly modified siRNA, thus poten-
tially limiting its utility. No in vivo data was provided in this
study.
Another interesting report described effects of small
molecules on two siRNA delivery approaches, namely
siRNALNPs and cholesterol conjugated siRNA (339). Ap-
proximately 45 000 compounds were screened in a GFP-
expressing cell line using a sophisticated automated fluo-
rescence microscopy approach. The study first determined
that the LNPs and the cholesterol-siRNA entered cells by
two distinct endocytotic pathways. Upon screening it was
determined that 25 compounds improved effects of LNPs
while 28 improved effects of cholesterol-siRNA, while only
two compounds influenced both. Further mechanistic stud-
ies placed the compounds into two groups; those that affect
uptake and those that affect endosome escape. By altering
the timing of the addition of the test compounds, it was de-
termined that some compounds acted directly on cells while
others bound to LNPs to exert their effects. The set of com-
pounds that acted via endosome escape seemed to do so by
several different mechanisms, suggesting that there are mul-
tiple ways to enhance delivery to the cytosol. Most of the
compounds reported in this study were active in the 10 uM
range. This study did not examine in vivo effects of the hit
compounds.
A very interesting report described the actions of a
known drug, dantroline, on enhancing the effects of a SSO
in the Duchene muscular dystrophy model (340). However,
as dantroline acts directly on the muscle Ryanodine re-
ceptor (RyR1), its effects may be limited to muscle cells.
Another study used a plant-derived sterol-glycoside to en-
hance the delivery of siRNA by lipid- or polypeptide-based
nanocarriers (341). In the case of the LNPs the small
molecule could be directly incorporated into the nanocar-
rier; this might be very advantageous in terms of making
sure that the enhancing molecule and the oligonucleotide
are in the same compartment.
In summary, several reports have shown that it is possible
to identify small molecules that substantially enhance the
pharmacological effects of oligonucleotides. Most of these
molecules act either by promoting uptake of the oligonu-
cleotide or by allowing its escape from endosomes. Al-
though it has been known for many years that high con-
centrations of classic lysosomotropic small molecules like
chloroquine can cause endosome escape, many of the re-
cently discovered small molecules achieve the same end but
by mechanisms quite distinct from chloroquine (336,339).
The small molecule enhancers described to date are largely
initial hits from high-throughput screens. Typically such
hits have less than ideal characteristics and substantial
medicinal chemistry work is required to develop related
molecules with greater potency, reduced toxicity and im-
proved pharmacokinetic and biodistribution properties. Al-
though this entails a great deal of effort it may be worth-
while especially if small molecule enhancers can improve
oligonucleotide effects in tissues other than the liver. The
possible role of small molecule enhancers in the clinical
development of oligonucleotides might be viewed as be-
ing akin to other drug adjuncts such as the use of beta-
lactamase inhibitors with penicillins.
Several particularly interesting recent publications on
oligonucleotide delivery are listed in Table 2.
CONCLUSIONS
This is a very exciting time for the field of oligonucleotide
therapeutics as a range of new approaches and potential
new clinical applications have emerged. In addition to its
traditional emphasis on ‘knocking down’ gene expression
usingASOs or siRNA, the field has embraced new strategies
including altering splicing patterns with SSOs and upreg-
ulating gene expression using antagomirs to miRNAs and
ncRNAs. A key issue for the future is whether the CRISPR-
Cas9 gene editing approach will move from its current re-
liance on viral vectors to greater use of non-viral delivery
systems and thus benefit from the technologies developed
for oligonucleotide delivery (162,342). One of the main ar-
guments for oligonucleotide-based therapeutics has always
been the ability to address targets that are not ‘druggable’
with conventional agents. This has now become even more
important with the emergence of a plethora of ncRNAs
that are involved in regulating many aspects of cell func-
tion. Clearly short oligonucleotide antagonists are the best
tools for regulating the ncRNA regulators.
In this promising landscape, delivery remains a key ob-
stacle. The issue is not simply to get oligonucleotides into
tissues, but to get them to the intracellular sites where they
actually function. It has been known for some time that the
biodistribution of an oligonucleotide at the chemical level
may have little to do with its functional biodistribution,
which is controlled by endogenous cellular activities (343).
Fortunately, challenging delivery issues are being addressed
using the large variety of innovative approaches that have
been described in this review. While no single delivery strat-
egy will be optimal in all situations, there are some clear
distinctions between the various approaches.
Currently ligand-oligonucleotide conjugates seem to of-
fer the greatest potential for future development. The fact
that they are distinct molecular entities makes them attrac-
tive for large-scale pharmaceutical development. Their rel-
atively small size assures a broad biodistribution, although
this may be tempered somewhat by rapid renal clearance.
Finally, the use of high affinity, highly selective ligands al-
low the possibility of very precise targeting to particular
cells or tissues. Despite these positive aspects there remain
many issues and unknowns. The exemplar of molecular
scale conjugates has been the triantennary GalNac conju-
gates that interact with the ASGPR. However, their success
may be predicated on a number of factors that are unique
to this situation. This would include: (i) the liver being a
highly perfused tissue thus allowing rapid conjugate uptake
to overwhelm renal clearance; (ii) the ASGPR being very
abundant and with a rapid turnover; (iii) a poorly defined
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Table 2. Selected recent publications on oligonucleotide delivery
Delivery approach Summary Significance Reference
LNPs Tested a large library of ‘lipoids’ for
siRNA delivery in cells and invivo
Discovered structural and pKa
features for design of effective LNPs
(175)
Polymer NPs Developed a hybrid lipid-polymer
NP for siRNA delivery
Polymer NPs had excellent
pharmacokinetic characteristics
and were effective in silencing in a
tumor model
(199)
Antibody-siRNA conjugates THIOMAB monoclonals with
siRNA conjugation at specific sites
were used to test siRNA delivery
Highlights the variability and







ASGPR; these provided effective
siRNA delivery to the liver
Exemplifies the advantages of
conjugates including defined
molecular properties, selectivity and
efficacy
(258)
Macromolecular scale conjugates Developed a targeted
polymer-PEG-siRNA conjugate
that was effective in delivery to the
liver
This is the initial report on
‘dynamic polyconjugates’ which
seem to be a promising approach
for delivery
(300)
Delivery to the CNS ASOs were used to antagonize a
lncRNA involved in a
neurodevelopmental disorder
Exemplifies effective use of ASOs in
the CNS
(73)
DNA nanostructures Developed tetrahedral DNA
nanostructures incorporating
siRNA with folate for targeting;
these were effective in silencing both
in cells and in a xenograft model
Provides a thorough study of the




Basic studies: description of
oligonucleotide uptake and
subcellular trafficking
These three studies used advanced
microscopic techniques to
quantitatively analyze the uptake,
trafficking and delivery of siRNAs
Provide important insights into the
intracellular fate of oligonucleotides
(158,181,182)
Basic studies: role of the trafficking
machinery in oligonucleotide
pharmacology
Used shRNA libraries to identify
genes important in determining the
effectiveness of oligonucleotides;
found that TSG101, an ESCRT
component, is vital
Demonstrates that the intracellular




Small molecules for oligonucleotide
delivery




oligonucleotides both in cells and
invivo; these compounds act by
releasing oligonucleotides from
unproductive entrapment in late
endosomes
Demonstrates that small molecules
can be used to manipulate the
intracellular trafficking of
oligonucleotides in a beneficial
manner
(336)
A limited number of publications have been selected as excellent examples of oligonucleotide delivery strategies or of basic studies on delivery.
propensity of the liver endomembrane system to be some-
what ‘leaky’ thus allowing oligonucleotide release to the cy-
tosol. The question remains whether comparable effects can
be achieved in non-hepatic tissues. Other receptors, for ex-
amplemembers of the integrin family, are expressed at levels
similar to ASGPR but may not recycle as rapidly. To attain
success in selective delivery to non-hepatic tissues it will be
essential to have a deep understanding of the biology of the
receptors being used for targeting; this would include their
abundance, turnover and pathways of intracellular traffick-
ing. Another key issue will be the valency of the ligand and
its topology. Receptor cross-linking can often accelerate in-
ternalization but it may also disturb the delicate balance
between receptor recycling and degradation. Finally, more
information about how ligand-oligonucleotide conjugates
traffic within the cellular endomembrane machinery will be
essential in optimizing their design.
Lipid and polymer-based nanocarriers remain impor-
tant tools for oligonucleotide delivery. As discussed above,
there are two major liabilities associated with nanoparti-
cles. The first is their limited biodistribution and the sec-
ond is toxicity due to use of polycationic components. How-
ever, both of these may be amenable to further refinement.
An emerging aspect is the development of unconventional
nanocarriers such as SNAs and DNA nanostructures. One
intriguing aspect of both of these technologies is that they
can explore a size range substantially smaller than the tra-
ditional 100 nm nanoparticle that may lead to improved
biodistribution. In the case of DNA nanostructures clever
computer-assisted design will allow the incorporation of
both aptameric targeting ligands and pharmacologically ac-
tive oligonucleotides into the structure itself. DNA nanos-
tructures also have the advantage of being precisely defined
entities, unlike conventional nanoparticles.
Targetedmacromolecular scale carriers based on proteins
or small non-toxic polymers may incorporate many of the
best features of both traditional nanocarriers and molecu-
lar scale conjugates. Thus they can include several ligands
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to provide a high avidity for the receptor, they can carry
multiple copies of the oligonucleotide, and they can be de-
signed to be small enough to penetrate the parenchyma of
many tissues. Additionally it has been possible to incorpo-
rate endsome-lytic capabilities into such conjugates (344).
However, the more features built into the conjugate the
greater the possibility of toxicity and the greater the diffi-
culty in scale-up and production.
Finally, the emergence of several types of small molecules
that enhance oligonucleotide effectiveness potentially pro-
vides on exciting new thrust in the oligonucleotide therapeu-
tics field. The field has tended to eschew medicinal chem-
istry or chemical biology approaches, viewing itself as an
alternative to those more conventional paths of drug devel-
opment. However, it is becoming clear that small molecules
can play a helpful role both in understanding and in improv-
ing the pharmacological effects of oligonucleotides. The
events of endocytosis and intracellular trafficking present
a complex drama supported by a cast of hundreds if not
thousands of proteins. Each of those proteins provides a
potential target for a small molecule that may influence the
trafficking process. Thus conceivably it may be possible to
find small molecules that enhance the actions of oligonu-
cleotides by affecting their endocytosis and trafficking in
many different ways. This might include altering receptor
internalization and recycling, affecting the rapidity or ex-
tent of endosome maturation, causing release of contents
from particular endomembrane compartments or steering
the trafficking flow to alternative compartments. There has
been relatively little work done on the chemical biology of
intracellular trafficking and it seems quite possible to design
high-throughput screens to identify small molecules that af-
fect distinct aspect of trafficking.
In summary, a variety of creative approaches have ad-
dressed the challenge of oligonucleotide delivery. It seems
likely that many of the issues in the oligonucleotide ther-
apeutics arena can be dealt with by judicious application
of delivery strategies that currently exist in mature form or
that are rapidly emerging. However, the creation of broadly
applicable delivery approaches that are highly effective and
without significant toxicity in humans remains to be at-
tained.Additionally these approachesmust be cost-effective
in the context of an increasingly pressured health care sys-
tem.
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